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CHAPTER  1 INTRODUCTION 
 
1.1 BACKGROUND 
Lung Function testing has been available as a widespread diagnostic test in the 
hospital setting for over 70 years. The term lung function is a collective name for a 
group of physiological tests that are designed to objectively assess a particular part or 
process of respiration. The advent of computerised analysis coupled with the 
standardisation of both equipment and testing procedures have helped to secure lung 
function testing an important place in the field of medical diagnostics.  
The primary test of lung function is called spirometry; its name comes from the Latin 
word ‘spirare’ (to breathe) and the Greek word ‘metron’ meaning to measure. In a 
spirometry test a subject is instructed in a series of very energetic breathing manoeuvres 
designed to objectively assess the flow and volume of exhaled air. The test is carried out 
using equipment known as a spirometer. The spirometer records exhaled air volume, 
and produces graphic and numeric information in the form of spirometric parameters 
and tracings that can depict and describe the mechanical properties of the lung. These 
spirometry values give a snapshot into how the lungs are functioning mechanically just 
as a blood pressure measurement gives a quick and painless indication of a patient’s 
cardiovascular status. The advantage of spirometry over other tests of lung function is in 
its simplicity and the fact that it can be performed as a stand alone test without the need 
for complicated computer software packages and gas analysis. It is also non-invasive 
and if performed and interpreted correctly spirometry has the potential to be a very 
effective screening tool for general lung health and in particular airflow limitation1.  
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The measurement of the maximal volume of gas expired from the lungs is called the 
forced vital capacity (FVC) (expressed as a function of time) and the measurement of 
the maximum flow expired after 1 second of forced expiration is called the forced 
expiratory volume in 1 second (FEV1). A spirometry test can be helpful in detecting the 
presence or absence of a condition associated with airflow limitation. Airflow limitation 
is defined as a ‘disproportionate reduction of maximal airflow from the lung in relation 
to the maximal volume that can be displaced’2. The degree to which the airways are 
limited or ‘obstructed’ can be determined by the ratio of FEV1 to FVC i.e. (FEV1/FVC). 
When the airways are obstructed, for example in an individual with asthma, the airway 
walls contract and so reduce the flow of air passing through them. Flow is often reduced 
out of proportion to the volume that can be exhaled and hence the ratio of FEV1 to FVC 
is reduced. To determine if a measured value is normal or abnormal it is compared to its 
equivalent ‘reference’ value. Reference values are values obtained from regression 
equations that have been calculated from the average values of a representative healthy 
population. Reference values are dealt with in more detail in chapter 3. 
Spirometry has been found to be an invaluable tool for the detection and management of 
lung disease and for this reason, spirometric parameters are used extensively for 
defining and categorising airflow limitation 3.  
Airflow limitation is the main characteristic of chronic obstructive pulmonary disease 
(COPD), a disease which is a major source of mortality and morbidity worldwide and 
which is projected to become the third leading cause of death in the world by 20204. 
COPD is an umbrella term that encompasses lung diseases which exhibit airflow 
limitation and includes asthma, chronic bronchitis, and emphysema. It is a preventable 
and treatable disease. Cigarette smoking is a major risk factor in the development of 
COPD5. However, in many smokers COPD can go undetected for many years, causing 
progressive loss of lung function at an accelerated rate. Population studies have shown 
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that simple spirometry testing can identify subjects at risk for undergoing accelerated 
lung function loss and can offer a valuable opportunity to identify individuals at risk of 
developing COPD by detecting airflow limitation in its early stages6,7. In two large 
European studies, spirometry was found to be the key indicator of an accurate diagnosis 
of COPD in the primary care setting by general practitioners8,9. Apart from its merits as 
a screening test for airflow limitation, spirometry is also a major independent and 
indirect predictor of cardiovascular morbidity and mortality10.  
 
1.2 AN ALTERNATIVE END OF TEST TO THE FVC 
The forced vital capacity (FVC) measurement is at the core of a spirometry test but it 
possesses an inbuilt variability in its primary measurement, lung capacity. All other 
spirometric indices are calculated from this capacity and therefore the ability to measure 
this parameter accurately is critical to achieving a successful test. Reproducibility of the 
FVC manoeuvre depends entirely on patient effort and co-operation; this requires that 
rigid guidelines be in place for determining an acceptable and reproducible test. The 
guideline that determines when a manoeuvre is complete and hence an accurate 
determination of expired volume is called the ‘end of test’ criterion. Current guidelines 
for the standardisation of spirometry testing in adults require a subject to inspire to 
maximal volume and then expel with both speed and force for at least six seconds or 
until no more than 25 millilitres (mls) of air are expelled over a period of 1 second. For 
reproducibility this manoeuvre is required to be repeated three times in succession with 
the goal of achieving two capacities within 150 mls of each other11.  
This end of test criterion is in turn dependant on the time taken to forcefully exhale all 
the air from the lungs, called the forced expiratory time (FET) which usually varies 
from subject to subject.  
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The majority of adults without airways disease have an average forced expiratory time 
of between six and seven seconds. In elderly subjects and subjects with airflow 
limitation, expiratory times are prolonged. The spirometry manoeuvre can then become 
physically exhausting to the patient as expiratory times stretch out in some cases for as 
long as 20 seconds, without adding  much more additional clinical information. During 
a testing session if the end of test criterion cannot be achieved the measurement is 
judged to be unacceptable and the manoeuvre is repeated. In the clinical setting it is not 
unusual to have patients with prolonged expiratory times that extend beyond 10 seconds 
and patients are frequently encouraged to continue expiring until the end of test criterion 
is satisfied. This can make the test unacceptable to the patient. 
 In response to the need for an alternative end of test criterion, a forced expiratory 
manoeuvre of a duration that could be easily attained by the majority of adults has been 
researched in recent times. This has led to the suggestion of a forced expiratory 
manoeuvre based on six seconds duration, FEV6, as a surrogate for FVC. A shorter 
manoeuvre such as FEV6 has the potential of reducing the burden of the test for the 
patient and lowering the overall testing time. It also has the potential of improving 
interpretation by reducing the variability of the volume measurement and making it 
statistically more accurate when compared with reference values for the same 
measurement. Ideally this surrogate measurement should at least retain the diagnostic 
capabilities of the traditional FVC manoeuvre.  
Figure 1.1 represents a graphical description of the FVC manoeuvre called a spirogram 
which is a plot of exhaled volume against time. Spirometry tracings will be covered in 
more detail in chapter 3. This shows the FVC and the FEV6 end of test point in a subject 
with a prolonged forced expiratory time.  
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FIGURE  1.1 SPIROGRAM DEPICTING BOTH FVC AND FEV6 END OF TEST POINTS1 
                 
 
1.3 AIMS OF THESIS 
The main aims of this research thesis are to assess the utility of the FEV6 manoeuvre in 
patients undergoing spirometry testing and in particular to determine if spirometric 
indices measured at six seconds are clinically useful in pulmonary function, especially 
in screening for early lung disease in smokers with an otherwise normal spirometry 
pattern. 
 
SPECIFIC QUESTIONS 
The main questions this thesis seeks to answer are: 
1. Are FEV6 and FEV1/FEV6 as or more clinically useful as the gold standard FEV1 
and FEV1/FVC? 
2. In our patient population can FEV6, FEV1/FEV6 be used instead of FVC and 
FEV1/FVC without surrendering relevant diagnostic information? 
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3. In older individuals where expiratory times are naturally longer, does the FEV6 
parameter diagnose airflow limitation as accurately as the FVC parameter using 
specific reference equations for this age group?  
 
 OUTLINE OF THESIS 
Chapter 2 gives an overview of the anatomy of the human respiratory system, and a 
brief description of the mechanisms involved in resting breathing. This chapter serves to 
provide a basic understanding of the mechanics of forced expiration which will be 
discussed along with the mechanics of airflow in Chapter 3. 
 
Chapter 3 looks at the physics of airflow and introduces the concept of airflow 
limitation. Sections on the physiology of the forced expiratory manoeuvre and a brief 
description of dynamic airway compression provide an introduction to the differences 
that exist between obstructed and normal airflow. 
 
Chapter 4 details the history of spirometry measurements, defines its parameters, 
introduces the equipment used to measure spirometry and outlines the guidelines and 
limitations associated with spirometry testing. 
 
Chapter 5 gives an overview of published research to date on the FEV6 parameter. 
 
Chapter 6 is a short overview of the methodology and the statistical analysis used in 
this study. 
 
Chapter 7 is a presentation and discussion of the results from each of the three studies 
designed to answer the questions posed by this research. 
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Chapter 8 gives a brief summary of the conclusions arrived at in this thesis and 
suggestions for further research into this topic. 
 
1.6    SUMMARY 
A shorter spirometry test manoeuvre that is easier for the patient to perform and that has 
the potential to increase the accuracy of the test by minimising measurement variability 
is an attractive feature for any diagnostic test. This is especially true for one that may 
have a future in screening for early COPD in at risk subjects such as smokers. An 
essential requirement of this possible surrogate test is that it at least upholds the 
diagnostic ability of the traditional spirometry manoeuvre. This will be investigated 
retrospectively in a patient population in this research.  
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CHAPTER 2  ANATOMY AND PHYSIOLOGY OF THE 
HUMAN RESPIRATORY SYSTEM 
 
2.1  INTRODUCTION 
This chapter gives a brief outline of the anatomy and physiology of the respiratory 
system. The respiratory system made up of a group of interlinking components; each 
component has its own unique structure, which serves to underlie its function. If any 
one of the components is affected by disease this will impact negatively on the system 
as a whole. The respiratory system has close links with the circulatory system of the 
human body, both work together as pumps to maintain a steady state within the body. 
The respiratory system grows as the body changes from birth to old age and also adapts 
to the many challenges that comes its way from the simple increase in ventilation 
required to facilitate exercise to the complex response to disease. This chapter aims to 
introduce the various structures of the respiratory system and give a brief description of 
their function. 
 
2.2 ANATOMY OF THE RESPIRATORY SYSTEM 
The main function of the respiratory system is to facilitate gas exchange. The 
respiratory system is divided into two components the upper respiratory tract and the 
lower respiratory tract1. The upper respiratory tract includes the nose, mouth, pharynx 
and larynx. The lower respiratory tract consists of the trachea, bronchi, bronchioles and 
alveoli. Each component of the respiratory system has a role to play in gas exchange. 
Gas exchange occurs when air rich in oxygen is inhaled into the lungs through the nose 
conducted through the respiratory system to the gas exchange areas of the lungs, called 
alveoli. Gas exchange occurs at this point and the carbon dioxide that is not wanted by 
the system is then expelled through the same pathway in the exhaled air. 
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 The anatomy of the lung lends itself to carrying out gas exchange as efficiently and 
effectively as possible by providing a clear pathway from atmosphere to alveoli. The 
airways connect the alveoli with the outside world, and play a pivotal role in the 
understanding of lung function in health and disease. Figure 2.1 shows the anatomy of 
the lungs. 
 
 
 
FIGURE  2.1  ANATOMY OF THE HUMAN LUNGS1 
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2.2.1 THE NOSE, PHARYNX AND LARYNX 
Air enters the respiratory tract through the nose and the mouth. Normal 
breathing occurs through the nose which has the advantage over mouth breathing in that 
nasal respiratory mucosa serves to humidify and filter the incoming air. In this mucosa 
are cells and glands lining the nose which secrete mucous to trap particulate matter and 
tiny course hairs which propel trapped particles towards the pharynx. The term pharynx 
comes from the Greek word meaning ‘throat’; it is a passageway for both air and food 
and is connected to the voice box or larynx. The primary function of the larynx is to 
prevent swallowed material entering the respiratory tract and it is also responsible for 
speech2. 
 
 2.2.2 TRACHEA 
The trachea is approximately 11-13 centimetres long in adults3 and is essentially 
a tube that is prevented from collapsing by c-shaped rings of cartilage that surround it. 
As shown in figure 2.2 the trachea is lined with ciliated pseudostratified columnar 
epithelium and goblet cells, which trap and remove debris before reaching the lungs. 
 
 
              FIGURE 2.2     CELLS OF MUCOSAL LINING OF TRACHEA2 
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2.2.3 BRONCHI, BRONCHIOLES AND ALVEOLI 
The trachea divides into two main branches called primary bronchi, left and 
right for each lung. The bronchi, just like the trachea, contain cartilage rings in their 
walls which allow for physical support. Each primary bronchus divides repeatedly in 
each lung giving rise to smaller branches called bronchioles which in turn subdivide 
into tiny microscopic branches called respiratory bronchioles. The respiratory 
bronchioles terminate into tiny saclike structures called alveoli where gas exchange 
occurs. A dense network of capillaries to maximise gas exchange surrounds each 
alveolus. There are approximately 400 million alveoli in each adult lung, and this figure 
is closely related to a persons total lung volume, that is larger lungs have been found to 
contain more alveoli4.  
 
 2.2.4 THE LUNGS AND BRONCHIAL TREE 
The lungs lie in what is known as the thoracic or chest cavity, a rigid but 
expandable structure that protects the delicate organs contained within it5. The two 
lungs are separated from each other by a mass of tissues known as the mediastinum. 
Each lung has an apex or upper part which is located about one inch from the clavicle, 
and a base or lower part that rests above the principal muscle of respiration called the 
diaphragm. The right lung has three lobes (upper, middle and lower) while the left lung 
has an upper and middle lobe with an appendage of the upper lobe called the lingual. A 
membrane called the pleural membrane surrounds each lung and consists of an inner 
layer called the visceral pleura and an outer layer covering the ribcage called the parietal 
pleura. These pleural layers are shown in figure 2.3. 
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FIGURE  2.3  PLEURAL CAVITIES OF THE LUNG3 
 
The space between these two layers is called the intrapleural cavity, and it contains a 
small amount of pleural fluid allowing lubrication of the membranes preventing friction 
during breathing. The intrapleural cavity or space plays a pivotal role in how the lungs 
inflate and deflate. 
 The geometry of the airways is analogous to a branching tree turned upside down. 
Where the tree first starts to branch at the trachea is referred to as generation zero and 
each set of branching thereafter gives rise to a new generation resulting in twenty-three 
generations in total6. Figure 2.4 shows the generation of branching from trachea to 
alveoli. The first sixteen generations are collectively referred to as the conducting 
airways, the remaining seven generations, which occupy most of the lung, are referred 
to as the respiratory zone and this is where gas exchange occurs.  
As each branch subdivides the radius of that branch is reduced and as the branches get 
smaller the total cross sectional area rapidly increases. The function of such a huge 
increase in cross sectional area is to maximise the potential for gas exchange by making 
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sure that as much surface area as possible is available for the diffusion of gas across the 
blood gas barrier. The blood gas barrier itself is extremely thin, approximately 0.3 μm, 
and its surface area is enormous, approximately 50-100 square meters7. 
 
FIGURE  2.4  GENERATION OF AIRWAYS FROM TRACHEA TO ALVEOLAR 
LEVEL4 
 
2.3 PHYSIOLOGY OF RESPIRATION 
While the primary function of the lung is to facilitate oxygen and carbon dioxide 
gas exchange, the chest muscles also play a major role in the mechanism behind 
breathing. The main respiratory muscles used are the diaphragm and the external 
intercostals. The diaphragm is a big dome shaped muscle that lies at the base of the 
lungs and when it contracts as it does during inspiration, it straightens out and in doing 
so increases the thoracic cavity volume. As in Figure 2.5 the external intercostals are 
located between the ribs and on contraction they have the power to pull the ribs up and 
in doing so push the sternum forward increasing the diameter of the thorax. The muscles 
used for expiration are called the internal intercostals and the abdominal muscles. As 
expiration does not actively involve muscle contraction it is referred to as a passive 
motion. Normally the expiratory muscles are only called on during the laboured 
breathing that accompanies strenuous exercise. However, in subjects with obstructive 
ventilatory diseases such as COPD, these muscles may be called on early in an 
expiratory effort for assistance. 
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FIGURE 2.5  MUSCLES OF THE THORACIC CAGE AND ANTERIOR 
ABDOMEN5 
 
2.3.1 PRESSURE GRADIENTS 
The lungs can be looked upon as elastic structures contained in a chest cage that is 
expandable. The lungs have inward recoil that is directly balanced by the outward recoil 
of the chest wall. Breathing requires continuous movement of the lungs to and from 
their resting position. Initiation of breathing requires that a pressure called the elastic 
inward recoil pressure (PL) of the lung is overcome. The ability of the lungs to 
overcome this pressure and expand and contract in a normal breathing motion relies on 
many factors working together, both inside and outside of the lungs8. Factors underlying 
the generation of airflow involve the behaviour of pressure differences in the respiratory 
system enabling the breathing process and preventing the lungs collapsing on 
expiration. During resting breathing air moves into the lungs by bulk gas flow from an 
area of higher pressure outside the lung to an area of lower pressure within the lung. 
The pressure outside the lungs called the atmosphere pressure (Patm) is higher than the 
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pressure contained in the alveoli called alveolar pressure (Palv) and so air will be 
automatically drawn into the lungs. 
 The opposite will occur when pressure in the alveoli is greater than that of the 
atmosphere and air will automatically leave the lungs on expiration. Between breaths, 
alveoli and atmospheric pressure are equal and no flow exists. There is a tension in the 
thorax between the lungs trying to collapse and the chest wall trying to spring out. As 
mentioned in section 2.2.4 the space between the chest wall and the lungs is called the 
intra pleural space. This space has its own pressure called the intra pleural pressure 
(Ppl) which serves to balance the two opposing forces and prevents the lungs from 
collapsing. At any given time the Ppl is negative with respect to Patm, and negative 
with respect to Palv, because the Palv are connected to the atmosphere by the branching 
airways. 
2.3.2 RESTING (BETWEEN BREATHS) 
Figure 2.6 depicts the pressure gradients of the lung before inspiration begins. 
 
FIGURE 2.6  PRESSURE GRADIENTS OF THE LUNG BETWEEN BREATHS6 
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Just before inspiration, Patm is equal to Palv and as the pressure is zero in the airways 
no air flow occurs and the diaphragm is in a relaxed position. The lungs remain inflated 
due to the Ppl remaining at a lower pressure than the pressure contained in the alveoli. 
Thus the airways remain patent as the negative intrapleural pressure is balanced by a 
positive pressure of the same magnitude holding the airway open. 
 
2.3.3  INSPIRATION (BREATHING IN) 
On inspiration, the muscles contract, expanding the rib cage and the attached pleural 
membrane and thus widening the intrapleural space and lowering its pressure. This 
difference in pressure or pressure gradient between intrapleural and alveolar regions 
pushes the lung wall outwards and the lungs expand increasing alveolar space and 
lowering the pressure there. When Palv is lower than Patm air will flow into the lungs. 
 Figure 2.7 depicts the pressure gradients existing in the lung at inspiration. As 
inspiration begins both the intrapleural and the alveolar pressure fall and air flows into 
the lungs.  
 
FIGURE 2.7  PRESSURE GRADIENTS OF THE LUNG ON INSPIRATION6 
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2.3.4 PASSIVE EXPIRATION (BREATHING OUT) 
On passive expiration, the diaphragm and the intercostal muscles relax allowing the 
lung to recoil. After inspiration there is additional air in the lungs, which causes Palv to 
be greater than Patm thus causing bulk gas flow out of the lungs. Figure 2.8 depicts the 
pressure gradients existing in the lung at passive expiration. 
 
 
FIGURE 2.8  PRESSURE GRADIENTSOF THE LUNG ON PASSIVE EXPIRATION6 
 
 
2.4 SUMMARY 
This chapter briefly outlined the anatomy and physiology of the human respiratory 
system. A section on the respiratory muscles used in breathing and a brief description of 
the mechanisms involved in normal breathing serve to provide a basic understanding to 
the mechanics underlying forced expiration which will be discussed along with the 
physics of airflow in Chapter 3. 
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CHAPTER 3   THE MECHANICS OF BREATHING  
 
3.1 INTRODUCTION 
Air in its journey from atmosphere to alveoli will experience an opposition to flow due 
to frictional resistance. The amount of resistance will depend on the linear velocity of 
the airflow which will in turn be affected by the airflow pattern and its location within 
the bronchial tree1. The nature and site of this resistance and the behaviour of airflow 
when it encounters the resistance gives an insight into how airways disease can have 
significant effects on lung function. The use of the forced expiratory volume at six 
seconds (FEV6) to determine airways obstruction accurately and reproducibly through 
spirometry testing is a key focus of this thesis and so this chapter will concentrate on the 
physiology behind the flow volume curve generated during a spirometry measurement. 
The first section of this chapter serves to introduce the concepts of airways resistance 
(RAW), the pattern of airflow, and the site of resistance. The second section will 
concentrate on the physics of airflow within the branches of the respiratory system. The 
final section details the physiology behind the spirometry manoeuvre and introduces the 
concept of airways obstruction from a physiological viewpoint. Tests of forced 
expiration reflect the mechanical workings of the lung. The physiological factors that 
determine maximal expiratory flow include the elastic properties of the lung, airways 
resistance and dynamic compression of the airways2. How these factors interact in 
healthy lungs provides the basis for understanding how disease affects lung function, 
allowing a better understanding of patterns of dysfunction that spirometry testing reveal. 
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3.2 AIRFLOW PATTERNS 
There are three main patterns of airflow that exist in the bronchial tree, laminar, 
turbulent, and transitional. Laminar flow is smooth, parallel airflow and can be found in 
smaller airways where the rate of airflow is slow. Turbulent flow as its name suggests, 
is a flow pattern that may be forward flow but unlike laminar flow it is non-parallel and 
non-linear. Turbulent flow occurs mainly in the large airways. The mixture of these two 
flow patterns, referred to as transitional flow, is most likely to exist at airway branch 
points. Figure 3.1 shows the various airflow patterns which occur within the human 
airways. 
 
FIGURE  3.1 AIRFLOW PATTERNS1 
 
 
3.3 PHYSICS OF AIRFLOW 
In order to understand the nature and contribution of frictional resistance encountered 
by air as it makes its way from atmosphere to alveoli, two relationships are used, the 
analogy to Ohm’s law and Poiseuille’s equation. The airways are analogous to an open 
tube, and as seen in figure 3.2 airflow occurs when there is a pressure difference 
between both ends of the tube P1 and P2. 
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 Ohm’s law for an electric circuit states that current is equal to voltage divided by 
resistance, and the equation reads: 
I = V/R Equation 3.1 
where V = Voltage, I = Current and R = Resistance. 
Applying by analogy, Ohm’s law to conditions existing in the airways, the equation can 
be rearranged as follows R = V/I, and the airways resistance RAW then becomes:  
RAW= ∆P/V                                                          Equation 3.2 
where ∆P=P1-P2, the difference in pressure from P1 to P2. 
 
FIGURE 3.2  AIR FLOW IN THE HUMAN AIRWAYS UNDER PRESSURE DIFFERENCE1 
 
The resistance RAW to airflow is obtained by dividing the pressure difference in the 
airway by the airflow rate V. Two variables considered in Ohm’s law are pressure and 
flow rate. Building on this a French physicist, Poiseuille, developed an equation to 
describe airways resistance through a tube in terms of the physical dimensions of the 
tube and the nature of the fluid moving through it (Figure 3.3) thus, 
  
  RAW= 8ηl / πr4                      Equation 3.3 
where  r = radius of tube , η = viscosity of flowing substance, l = length of tube,  
 π = 3.14 
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FIGURE  3.3  ILLUSTRATION OF POISEUILLE’S DESCRIPTION  OF LAMINAR 
AIRFLOW APPLIED TO THE HUMAN AIRWAYS1 
 
 
Poiseuille’s equation states that the frictional resistance to flow is directly related to 
viscosity of the air and the length of the tube and indirectly related to the fourth power 
of the tube radius. According to Poiseuille’s equation the radius of the tube is critical in 
determining the magnitude of airways resistance. If the radius of the tube is reduced by 
approximately 50% with no change to either tube length or the viscosity of the air 
flowing through it, the calculated resistance would increase by sixteen-fold, or the 
driving pressure would need to increase by sixteen-fold to maintain the same flow. 
However unlike Poiseuille’s equation, which was derived using rigid smooth tubes that 
encourage a laminar flow pattern, the human airways are distensible and have 
continuously branching tubes of various radii, where both laminar and turbulent flow 
co-exist. The transition from laminar to turbulent flow can be indicated by a number 
called the Reynolds’ number. 
  Reynolds’ number = vd/ η  Equation 3.4
                      
where  = density of fluid, v = linear velocity, 2r = diameter of tube, η = viscosity of 
fluid 
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The size of the Reynolds’ number will to a large extent determine whether flow in a 
particular branch will be laminar or turbulent. Turbulence occurs when the Reynolds’ 
number is very large, something in the magnitude of 2000, when the velocity of flow is 
high and the tube diameter is large, for example at the trachea. In the smallest of 
branches, the terminal bronchioles, Reynolds’ number is approximately 1 and this 
dictates that the type of airflow there will be laminar. For the majority of the bronchial 
tree, flow is transitional moving from areas of turbulence to areas of laminar flow 3. 
 
3.4 SITE OF AIRWAYS RESISTANCE (RAW) 
The nature and site of airways resistance is important in understanding the mechanism 
behind lung disease as resistance to airflow is likely to be increased in certain lung 
diseases4. As the bronchial tree subdivides and its branches become smaller and more 
numerous, the diameter of the terminal bronchioles are many times smaller than the 
diameter of the bronchi. As mentioned in chapter 2, section 2.2.4, each set of airway 
branchings gives rise to a new generation resulting in twenty-three generations in total. 
The fourth and eight order of branching include the medium sized bronchi. The eight to 
twelfth generations include the bronchioles and generation sixteen onwards include the 
terminal bronchioles. Figure 3.4(A) shows the position of airways resistance in relation 
to the order of generation of branches in the bronchial tree and Figure 3.4 (B) shows the 
relationship of linear velocity and cross sectional area through each generation of 
branching. 
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FIGURE 3.4 (A) SITE OF AIRWAYS RESISTANCE IN THE BRONCHIAL TREE2 
 
 
 
 
FIGURE  3.4 (B) RELATIONSHIP OF LINEAR VELOCITY AND CROSS SECTIONAL AREA 
IN THE BRONCHIAL TREE2 
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According to Poiseuille’s equation (equation 3.3) the major site of airways resistance 
should be in the location of the smallest airways with their small radii at generation 
sixteen onwards. However, studies have shown this is not the case, but rather the 
medium size airways have the greatest airways resistance5. Small airways (< 2 mm in 
diameter) have the potential for greater airways resistance; however small airways 
branch repeatedly and in doing so create a large cross sectional area for airflow. This 
large cross sectional area dictates that flow in the small airways is slower and is laminar. 
An analogy to electrical resistors can also be used to describe the behaviour of airways 
resistance in the small airways. Like resistors in an electrical circuit, airways through 
the generations of branching from the trachea to the bronchi to the bronchioles can be 
described as being in series. Resistances in series are added to give the total resistance 
(Rtot). 
Rtot = R1 + R2 + ……..Rn   Equation  3.5
   
The total resistance of a given generation is greater in airways that exceed 2 mm (figure 
3.4). When all the resistances of a generation are added together, the overall resistance 
of that generation decreases, this occurs because these resistances are in parallel and the 
total resistance is obtained from the inverse of the sum of the reciprocal of each 
resistance 
         RTOT = 1/ 1/R1 +1/R2 +……… 1/Rn     Equation   3.6 
          1/RTOT = 1/R1 +1/R2+……1/Rn                 
The resistances arranged in parallel can be added as reciprocals of their individual 
resistances therefore yielding a far less total RAW. This arrangement negates the effect 
of a reduced diameter on the resistance. The first studies conducted to determine the site 
of airways resistance was performed on dogs and later on humans using a catheter 
inserted into the lungs in an attempt to bypass the large airways.  
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These studies proved that small airways resistance was only a minor contributor to 
overall resistance6. As the small airways have little resistance, airways disease can go 
unnoticed for many years and this area is referred to as the ‘silent zone’ of early airways 
disease. 
 
3.5 FORCED EXPIRATORY MANOEUVRE 
Expiration in normal breathing conditions is a passive process but when air is physically 
expelled from the lungs the airways become compressed and close. This compression is 
a natural phenomenon occurring only at very low lung volumes in young healthy 
subjects. However disease of the respiratory system can cause this compression to be 
exaggerated and to occur earlier in the forced expiration than would naturally occur in 
healthy airways. This early compression is also apparent in the lungs of healthy elderly 
subjects mainly due to the loss of elastic recoil that accompanies the natural ageing 
process of the lungs7. The site and nature of airway compression can be measured 
indirectly by performing a breathing manoeuvre called a forced expiratory test on 
equipment known as a spirometer. The spirometer produces a graph called a flow 
volume curve which provides visual evidence of the airway compression.  
Spirometry testing requires a subject to inspire to a maximum volume called total lung 
capacity (TLC) and then blow out very fast into a spirometer until a minimum volume is 
reached called the residual volume. By ‘blasting’ the air out of the lungs a force is 
applied to the thoracic cavity and lungs causing the pressure in the alveoli (Palv) to 
increase well above atmospheric pressure (Patm), which results in air leaving the lungs. 
Figure 3.5 depicts a typical flow volume curve produced from a forced expiratory 
manoeuvre.  
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FIGURE 3.5  FLOW VOLUME CURVE ON NON-DISEASED AIRWAYS3 
 
Flow begins at zero and rises rapidly to a peak flow point, the curve declines over most 
of the expiration as air is forced from large to medium to small airways until reaching a 
zero volume. The shape of a flow volume curve is very reproducible for non-diseased 
lungs but can be altered by airways disease in characteristic ways. This is due to a 
mechanism known as dynamic airway compression or flow limitation.  
The site and extent at which flow limitation occurs will ultimately determine the shape 
of the flow volume curve. Section 3.7 will introduce the physiology behind the 
mechanism of flow limitation and provide a brief summary of some of the theories used 
to explain flow limitation. 
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3.6 DYNAMIC AIRWAY COMPRESSION/ FLOW LIMITATION 
Dynamic airway compression as its name suggests describes what happens to the 
airways as air is physically forced out of the lungs with speed. The way in which the 
airways respond to this dynamic compression is different in health and disease. 
Spirometry testing has made it possible to understand the mechanical events that limit 
maximal exhalation, and to locate with the aid of flow volume curves the location of 
this dynamic compression. 
In the build up to a forced expiration, a maximum breath is inhaled to TLC and in doing 
so the ribcage is expanded allowing the lung to hold this maximum volume, and as the 
lungs are now stretched the pleural pressure is at its maximum. The initial burst of air, 
called the peak flow point is effort-dependent and produced entirely by expiratory 
muscle force. Beyond the peak flow point the expiratory muscles fail to play a 
significant role and elastic recoil takes over to maintain the expiratory flow. The change 
from effort-dependent to effort-independent flow and the pressures that drive the flow at 
this point is called flow limitation. There are three theories used to explain flow 
limitation, the equal pressure point by Mead et al.8, the waterfall theory by Pride et al.9 
and the wave speed theory of flow limitation by Dawson et al.10. A detailed description 
of the equal pressure point followed by a brief summary of the waterfall and wave speed 
theories of flow limitation follows. 
As described in chapter 2 section 2.3.1, the normal breathing cycle is brought about by 
changes in pressure gradients. Pressure gradients behave differently when air is forced 
at speed from the airways and the following sections will describe this process. 
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3.6.1 TIDAL BREATHING 
Tidal breathing is the pattern of breathing performed unconsciously at rest. On average 
a subject will inhale approximately 500ml of air with each tidal breath and exhale the 
same amount. Before inspiration begins the respiratory muscles are at rest and the 
elastic recoil of the lung (Pel) and the elastic recoil of the chest are equal but opposite 
and the pressure inside the alveoli (Palv) is at the same pressure as the atmosphere 
(Patm). As mentioned in chapter 2, section 2.3.1, a pressure gradient needs to exist 
before air can flow, and air will only flow from an area of higher pressure to one of 
lower pressure and since Palv = Patm there is no airflow. During inspiration the 
diaphragm contracts and in doing so compresses the abdominal contents and 
decompresses the contents of the thorax causing the pleural pressure to fall. As Ppl falls, 
Palv falls by an equal amount becoming sub atmospheric and creating a pressure 
gradient. Air flows into the lungs down the pressure gradient from mouth to alveoli. The 
lungs and chest expand in volume, and this causes the recoil pressure of the lung to 
increase until a new equilibrium is reached. Equilibrium exists after inspiration and 
before expiration begins. Air flows down the pressure gradient until the lung reaches a 
new equilibrium volume at which Palv equals zero and the gradient for flow ceases to 
exist. Lung and chest wall are fully expanded. 
During expiration the respiratory muscles relax, allowing the lung to recoil causing an 
abrupt increase in Ppl to a less negative value. Additional air in the lungs causes the 
Palv to rise above Patm and air flows out of the lungs. Lung volume and chest wall 
dimension decrease as air flows out causing lung recoil pressure to fall until a new 
equilibrium is reached. At end expiration, the pleural cavity and the alveoli return to the 
pressure relationship they had at the start of inspiration. 
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3.6.2 FORCED BREATHING 
As detailed in Chapter 2, the lungs are elastic structures and they have an inbuilt 
tendency to want to recoil, like a spring, a tendency called the elastic recoil pressure of 
the lung (Pel). In the build-up to a forced expiratory manoeuvre, a deep breath is taken 
into the lungs and they stretch, and as the lungs stretch, they have an even greater 
tendency to want to spring back into the resting position. In order to overcome this 
tendency and expand the lungs to their maximum, a pressure known as the 
transpulmonary pressure (PLel) needs to be increased. The transpulmonary pressure is 
the pressure difference across the lungs. At the start of a forced expiration Ppl rises very 
steeply as the expiratory muscles contract and the lung volume decreases. The Palv 
increases and forced expiratory flow begins. At this point a pressure gradient exists 
from mouth to alveoli, and as flow occurs the pressure inside the airway becomes less 
than the pressure outside the airway. The pressure falls steadily going from the alveoli 
where it is high, falling steadily through the bronchi (Pbr) to the level of the mouth 
(Pmo) and out into atmosphere (Patm). This pressure fall occurs because of the fall in 
resistance that is greater towards the trachea where the number of parallel airways 
decreases. In addition, the gas velocity increases towards the trachea, as the cross 
sectional area of the airways decreases. As this exhalation continues, lung volume 
decreases, causing a fall in the static recoil pressure which reduces the transpulmonary 
pressure. Somewhere along the airway, the transmural pressure will become negative, as 
Ppl will exceed the airway pressure, resulting in compression of the airways. 
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FIGURE 3.6  CONDITIONS EXISTING IN THE RESPIRATORY SYSTEM DURING 
FORCED EXPIRATION4 
 
3.6.3 EQUAL PRESSURE POINT THEORY 
By exhaling a full breath of air with maximal force, through a tube, as in a spirometry 
test, a large force is applied to the thoracic cavity, causing both pleural pressure (Ppl) 
and alveolar pressure (Palv) to increase well above atmospheric pressure. Then as flow 
begins the pressure along the airways from the alveoli to the mouth drops and the 
airways tend to compress and limit flow. Once the expiratory flow becomes limited, the 
airways at the alveoli are distended whereas the airways at the trachea are compressed. 
This led investigators to believe that there must be points between the trachea and the 
alveoli where airways are neither compressed nor distended. Such points were then 
called equal pressure points (EPP), where the pressure inside the airway had to be equal 
to the pressure outside the airway. The airways could be then looked upon as two 
separate segments, a distended segment and a compressed segment. At the EPP the 
limiting flow becomes the pressure outside the airway called the intrapleural pressure or 
 
 
 
35
the elastic recoil pressure (Pel). This pressure is the driving pressure, and if a subject 
tries to physically force the breath out at the end of expiration by using respiratory 
muscles to increase intrapleural pressure further, this will have absolutely no affect on 
the driving pressure, making flow independent of effort. The maximum flow expelled 
however will decrease with decreasing lung volumes, because the difference between 
alveolar and intrapleural pressure decreases as the airways narrow up to the EPP. As the 
lungs empty the EPP moves into increasingly smaller airways and continues on until the 
airways close, trapping some gas in the alveoli at a point known as the residual volume 
of the lung. 
This expiratory mechanism is called dynamic airway compression and is what gives the 
characteristic linear or slightly concave shape to the maximum expiratory curve on the 
spirometer tracing. The curve has a maximum flow/volume envelope that is remarkably 
consistent even with variable expiratory efforts. Figure 3.7 shows a forced expiratory 
tracing performed with various efforts and at various starting volumes. 
 
FIGURE 3.7  MAXIMUM EXPIRATORY EFFORT CURVES WITH VARIABLE SUBJECT 
EFFORT (A,B,C,D)5 
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  When the maximum flow volume envelope is reached the decline in expiratory flow as 
the lung empties will always follow the same pathway regardless of the starting volume 
or effort. For each point of the curve, a maximum flow cannot be exceeded regardless of 
the effort exerted.  
 
3.6.4 WATERFALL THEORY  
Following from the equal pressure point theory, and in an effort to explain flow 
limitation researchers modelled the lung as a resistance between the alveoli and a point 
downstream from the EPP where transmural pressure reached a critical value that was 
enough to limit flow. This is analogous to a waterfall, where flow is independent of the 
height of the falls, just as maximal expiratory flow limitation is independent of the total 
driving pressure between alveoli and mouth.9 
 
3.6.5 WAVE SPEED THEORY  
Dawson and Elliott10 showed that maximal expiratory flow occurs when the linear 
velocity of gas at the flow limiting segments, which they termed choke points, becomes 
equal to the speed at which a pressure wave travels along the airways to the alveoli. 
This high linear velocity prevents transmission of downstream pressure through choke 
points, so that flow becomes independent of pressure. 
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3.7  OBSTRUCTIVE VENTILATORY PATTERN 
Spirometry testing can reveal patterns in the form of numerical values and flow 
volume curves that are typical of specific lung diseases. These patterns are used to make 
judgements in clinical practice on the site and nature of the disease process within the 
lung in conjunction with other clinical data. Airways disease can be broadly divided 
into two main groups by the nature of their structural impairment termed obstructive 
and restrictive ventilatory disorders. Obstructive disorders as their name suggests, 
‘obstruct’ the flow of air out of the lungs causing an increase in airway resistance, and 
included asthma, chronic bronchitis, emphysema and chronic obstructive pulmonary 
disease (COPD). Restrictive lung disorders can affect the bellows action of the lungs 
and chest wall by ‘restricting’ the process of inflation. Restrictive diseases include 
thoracic wall deformity and pulmonary fibrosis. An obstructive ventilatory airflow 
pattern typical of a subject with COPD produces a flow volume curve as shown in 
figure 3.8. A normal curve is superimposed for comparison. In obstructive airways 
disease the airway walls loose tension and become flaccid. During a forced expiratory 
manoeuvre, the airways collapse and the equal pressure point occurs nearer the alveoli 
than in healthy subjects producing a curve that has a ‘scooped’ out appearance. 
Obstructive diseases are also likely to cause an increased resistance in the smaller 
airways and an elastic recoil pressure occurring closer to the alveoli, which leads to 
greater compression and greater airflow limitation11. 
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FIGURE 3.8  FLOW VOLUME CURVE OF (A) SUBJECT WITH NO AIRWAYS DISEASE 
AND 
(B) SUBJECT WITH SEVERE AIRWAYS DISEASE6 
 
 
 
3.8 SUMMARY 
This chapter outlined the mechanics of airflow. Sections on the physiology of the forced 
expiratory manoeuvre and a brief description of dynamic airway compression serve to 
introduce an understanding of the differences that exist between obstructed and normal 
airflow in terms of the site of airways resistance. The next chapter will deal with the 
parameters measured from a spirometry test. 
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CHAPTER 4. SPIROMETRIC PARAMETERS AND FLOW 
VOLUME CURVES 
 
4.1 INTRODUCTION 
The way in which the lungs behave mechanically differs in health and disease 
and depending on the site and nature of the disease this difference can significantly 
affect the lungs ability to perform its main function of gas exchange. An understanding 
of the volume and flow rates of the lung is necessary in order to assess the degree of 
lung impairment. Often in individuals with suspected lung disease, spirometry is the 
first test used in the investigation stage. The values generated from a spirometry test 
provide graphic and numeric information, which depict and describe the mechanical 
properties of the lung, chest wall and respiratory muscles. Although the breathing 
manoeuvre required for spirometry is far removed from a normal breathing pattern, the 
results and graphs created are very reproducible for a given person, and can show 
characteristic patterns of dysfunction in lung disease when present. Interpretation of 
spirometry results involves comparison of measured values with ‘normal’ reference 
values generated from a population of healthy individuals matched for age, height, 
gender and ethnicity.  
The equipment necessary to carry out this test is called a spirometer. 
Spirometers come in various formats. Small portable stand-alone versions are 
commonly used in clinics whereas more complex devices tend to be found in 
specialised hospital-based lung function equipment. This chapter will focus on the 
parameters and tracings produced from a spirometry test, and how these values are 
interpreted. Section 4.2 will cover the evolution of the spirometry measurement. Section 
4.3 details spirometer devices the principles behind the measurement and quality control 
 
 
 
42
in the measurements. A section describing how a spirometry measurement is performed 
followed by a section on the various parameters and tracings associated with spirometry 
testing. The interpretation of spirometry results and a section on reference values are 
covered in the final section of this chapter. 
4.2 THE EVOLUTION OF SPIROMETRY MEASUREMENTS 
In 1846 an English surgeon John Hutchinson published in the Lancet journal the first 
study of its kind documenting, measuring and advocating the importance of the 
physiological measurement of lung function. Hutchinson invented a calibrated bell, 
inverted in water, in order to be able to measure the volume of exhaled air from fully 
inflated lungs.  This measurement he called the vital capacity (VC), meaning the 
capacity to live, as he realised that compromise of vital capacity was predictive of 
premature death.  Hutchinson’s studies showed that vital capacity in normal healthy 
subjects was directly related to standing height, and inversely related to the age of the 
individual. He also observed that vital capacity became mildly reduced following a 
large meal. In his first article published in 1846, he reported on the measurement on 
2,130 individuals, including deceased patients. Hutchinson would go to the morgue 
immediately following death and insert into the trachea the equivalent of an 
endotracheal tube with a stopcock, and inflate the corpse with a bellows until no more 
air could enter. He then released the flow of air into his spirometer, observing that the 
lungs and thorax emptied under elastic recoil to a minimum volume called the residual 
volume. Hutchinson became a consultant to the insurance industry of London, 
advocating the need for spirometry measurements of vital capacity to be used in 
actuarial predictions for life insurance brokers.  However, Hutchinson’s spirometer was 
not widely accepted in London and at the age of 41 he emigrated to Melbourne, 
Australia where all further use of the spirometer was abandoned. Hutchinson spent his 
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final years on the island of Fiji, where a statue was erected in his memory by the 
Thoracic Society of Australia and the British Thoracic Association in 1990 1,2,3,4,5,6  
 
FIGURE 4.1  SILHOUTTE OF JOHN HUTCHINSON AND HIS SPIROMETER1 
 
Hutchinson’s research introduced to the world the first water-sealed type of spirometer 
which some aspects are still evident in today’s devices.  It was not until the 1940 s that 
the concept of measuring the rate of volume exhaled was introduced, born from the 
observation that individuals with asthma, emphysema, chronic bronchitis and other such 
obstructive ventilatory disorders, exhaled at a slower rate than healthy individuals. The 
forced expiratory volume (FEV) was first described by Tiffeneau and Pinelli7 working 
in Paris, in December 1947, more than 100 years after the first measurement of lung 
function was made by Hutchinson. In those 100 years, spirometry had been considered 
an important tool but could not be utilised fully, mainly because the technology was not 
sufficiently sensitive to measure instantaneous flow. A more precise evaluation of the 
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dynamic behaviour of the lungs only became possible after the description of the 
pneumotachograph by Fleisch8 in 1925.  
Soon afterwards, Engelmann10 noticed that asthma was characterised by a 
marked prolongation of the expiratory phase, and after epinephrine was administered to 
the patient, a normal expiratory phase was observed. Hermannsen11 was the first to 
record the maximal ventilatory possibilities during a sustained voluntary effort in 1933, 
after this several investigators started to relate the sensation of dyspnoea to the 
maximum breathing capacity (MBC). A study published in 1938 by Barrack12 computed 
the expiratory and inspiratory flow, and expressed them in cubic centimetres per second.  
This concept gave a greater insight into the patency of the airways and equipped the 
spirometer with a rotating drum, where volume changes could be recorded as a function 
of time. Gambits13 also in 1938 realized that the level of maximum breathing capacity 
MBC is determined by the size of the vital capacity (VC). He proposed to use the ratio 
MBC (l/min)/ VC (l), subsequently called the capacity ratio, and nowadays referred to 
the FEV1/VC ratio. Courante et al.14 observed a striking decrease in the rate of 
expiration in patients diagnosed with emphysema.  
Other studies at this time showed that the time necessary for a full maximal 
expiration was markedly different for normal subjects compared to patients with 
obstructive ventilatory diseases, for whom forced expiratory times were prolonged. Cara 
et al.15specified that a subject must breathe out as quickly, strongly, and  completely as 
possible, during a forced expiratory manoeuvre, and that correction factors for 
barometric pressure and temperature must be considered and applied to the 
measurement for accurate and reliable recordings to be made. Tiffeneau’s group16 made 
several more important observations which are still largely valid today; they had noticed 
that during exercise both the circulating air or tidal volume and the respiratory 
frequency tend to increase. They proposed to measure the maximal volume that can be 
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expired in a space of time corresponding to the usual duration of an expiratory phase 
during exercise. They called this measurement the “capacitē pulmonaire utilisable a 
l’effort” (CPUE). The CPUE was proposed to be equal to the largest volume that can be 
expired in one second. This is now known as the forced expiratory volume in one 
second FEV1. 
Despite these observations and studies, the contribution of these French investigators 
remained largely ignored. A group of respiratory investigators in the US met in April 
1950 to standardise the definitions and symbols used in respiratory physiology.  In the 
US, at this time, it was Gaensler’s work17on the analysis of the forced expiratory 
volume that was fast becoming accepted. Gaensler’s adaptation of the water-sealed 
spirometer using a micro switch to time the forced expiratory breath, meant that for the 
first time airway obstruction could be assessed. He proposed to calculate air velocity 
index (AVI) and made measurements in 435 patients. In 23 normal patients he found an 
AVI above 1, and similar results after a lobectomy. However in 36 asthmatics the AVI 
was reduced. He also noted that the slope of the expiratory tracings was very steep 
during the first seconds, and that an accurate measurement of the volume of air could 
not be made. He adapted the spirometer to introduce a time element, and thus the timed 
VC was born.  
Gaensler’s studies concluded that a healthy individual could exhale approximately 80% 
of their capacity in the first second of a forced expiratory blow.  Any forced expiratory 
measurement falling short of this critical measurement could be interpreted as indicating 
the presence of airways obstruction. 
 The timed VC then started to gain more popularity over the MBC. Fowler et al.18 
provided evidence that there was no initial period of sustained constant flow rate, except 
occasionally in normal persons during somewhat sub-maximal effort.   
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The acceleration of the airflow during the first several tenths of a second was, in fact, so 
large that an accurate recording of this portion of the trace with a spirometer was 
considered uncertain. Therefore, they advocated measurement of the average flow over 
the middle of a rapid maximal expiration: the maximal mid-expiratory flow rate was 
born. They demonstrated a graphical method to assess airway obstruction, and were the 
first to measure and document the parameter FEF25-75% that is the mid section of the 
forced expiratory tracing. This and other parameters were used with more confidence to 
differentiate healthy airflow from obstructed airflow. Ten years after his first work on 
the subject, Tiffeneau published his monograph summarising all his work on the 
VEMS, the “volume expiratoire maximum seconde”, the term that superseded the 
CPUE 19. The British Thoracic Society adopted recommendations on terminology for 
measurements of ventilatory capacity they replaced the term ‘timed VC’ with the 
expression we know today as the ‘forced expiratory volume over a stated interval of 
time’ and hence the FEV1 and FEV3 and FEV6.  The nomenclature accepted today is the 
VEMS in French and the FEV1 in English.  After over 50 years, the VEMS and the 
FEV1 have become used daily by respiratory physiologists and physicians to measure 
and document respiratory disease. 
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4.3 SPIROMETER DEVICES 
4.3.1 INTRODUCTION 
Spirometer devices are specifically designed to collect measure and display exhaled 
flow and volume. There are two types of spirometer, volume displacement and flow 
sensing. In a volume displacement spirometer exhaled volume is the primary signal and 
flow is obtained from differentiation of volume with respect to time. A flow sensing 
spirometer will measure flow directly and then integrate this signal to obtain a volume 
measurement. Regardless of the type of spirometer used it must conform to a set of 
specific standards as recommended by the joint working parties of the European 
Respiratory Society (ERS) and the American Thoracic Society (ATS) 3 (Appendix A).  
Conformity of equipment has led to a major reduction in the measurement 
variability that was previously witnessed between spirometers, but the requirement for 
accurate and reproducible measurements is still the responsibility of the individual 
providing the spirometry service16. Maintaining high standards of accuracy require that 
a robust quality control (QC) system is in place. Instrument quality control involves two 
related procedures called calibration and quality control-checks. Calibration is the 
procedure for establishing the relationship between spirometer-determined values of 
flow and volume and actual flow and volume. A quality control check is the procedure 
used to validate that the spirometer is within its calibration limits.  
The modern spirometer is a lightweight portable medical device with a built-in 
microprocessor that can store and display many parameters, print tracings and even 
offer a computerised interpretation based on algorithms. Despite the many advances in 
medical technology, the underlying principle and the measurement of spirometry stay 
true to the original volume displacement spirometer introduced to the world by 
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Hutchinson more than a century ago. The type of spirometer used to produce the results 
in this research thesis is a flow-sensing anemometer type known as a mass flow sensor.  
 
4.3.2 MASS FLOW SENSOR 
The mass flow sensor is an application of an anemometer. The function of this device is 
based on King’s law of energy loss from a heated wire4. As can be seen in figure 4.1 the 
mass flow sensor contains two metallic filaments situated in a tube that is tapered to 
encourage laminar flow. One filament wire is for sensing and the other operates as a 
reference. The reference filament tracks the temperature of the airflow passing by it. 
The sensing filament is maintained at a preset temperature approximately 50˚C above 
the temperature of the reference. When a patient breathes into the mass flow sensor the 
gas in the exhaled breath cools the sensing filament.  
To maintain the sensing filament at the same offset temperature more power is required 
to be delivered to it through an electrical circuit. The quantity of current delivered to 
maintain the temperature is proportional to flow. This flow signal is then integrated to 
obtain volume. The function of the circuit is to continually heat the sensing filament to a 
constant temperature above the reference filament and therefore above the gas 
temperature. To enable this to happen, the circuit ‘senses’ the filament temperature by 
reading the filaments electrical resistance. 
 The amount of electrical current required to raise the filament temperature back to its 
designated temperature is known from the control circuitry.  The current flows in one 
direction only and is driven on the inside pins (figure 4.2). The second set of pins reads 
the voltage drop. The voltage drop occurs when gas molecules remove heat from the 
sensing filament. This voltage drop is fed through a series of pins, cables and cable 
connectors back to the circuitry where it is read.  
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   FIGURE  4.2  MASS FLOW SENSOR2 
 
FIGURE  4.3  MASS FLOW SENSOR CIRCUITRY2 
 
4.4 INDICATIONS FOR SPIROMETRY TESTING 
Spirometry testing has the advantage of been non-invasive, well standardised, relatively 
short in duration with results available immediately post-test, and for these reasons it is 
indicated in a variety of clinical situations5 included in Table 4.1. As outlined in chapter 
1, spirometry testing is gaining acceptance as an essential tool not only for quantifying 
the degree of lung impairment in COPD, but also as a screening tool for the detection of 
this disease in individuals at risk, such as smokers 6,7. 
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TABLE 4.1 INDICATIONS FOR SPIROMETRY TESTING 
Diagnostic 
 
To evaluate signs and symptoms 
To measure the effect of disease on lung function 
To screen individuals at risk of having pulmonary disease and 
assess prognosis 
To assess pre-op risk 
To determine the degree of  reversibility  
 
Monitoring 
 
To assess therapeutic intervention 
To describe the course of disease that affects lung function 
To monitor those exposed to agents known to be toxic to the 
lungs 
To monitor for drugs known to have pulmonary toxicity 
 
Disability/Impairment 
 
 
To assess patients as part of a rehabilitation programme 
To assess risk as part of an insurance evaluation 
Public Health 
 
Epidemiological surveys 
Derivation of reference equations and in clinical research. 
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4.5 MEASUREMENT TECHNIQUE  
Spirometry results depend largely on patient effort and understanding. The 
enthusiasm and attention to detail of the individual carrying out the test also plays an 
important role in obtaining accurate and reproducible measurements. In order to assure 
reproducibility between spirometry tests and also between test centres, guidelines on 
spirometry measurement have been published. Table 4.2 provides a summary of these 
guidelines8. Maintaining the comfort and safety of the subject during testing is as 
important as the technique itself. The first measurement made in a spirometry test, is the 
subject’s standing height. Special attention must be given to this measurement as height 
together with gender and age are essential in acquiring the correct reference values used 
for interpretation of results. Interpretation and reference equations are covered in section 
4.9. During a spirometry test, subjects are encouraged to remain seated upright 
throughout, as forced manoeuvres can cause prolonged interruption of venous return to 
the thorax causing a sudden dizziness referred to as syncope. Clothing around the chest 
and neck is loosened to allow for full chest expansion and a nose clip is used to ensure 
there are no air leaks during the manoeuvre. Every effort must be made at this 
preparation stage to ensure that the patient is comfortable. Patients are asked to sit 
straight with both feet on the ground. Tight clothing is loosened and water and tissues 
are made available. Spirometry begins with a maximum inhalation followed by a forced 
expiration that rapidly empties the lungs. Despite efforts to maintain patient comfort 
during a spirometry test the manoeuvre can prove to be a very uncomfortable 
experience for patients with airways disease and elderly patients, as the sustained long 
expiratory efforts required in the measurement can be tiresome. 
The start of expiration must be swift, without any hesitation. The expiratory effort must 
continue for as long as possible or until a plateau in exhaled volume is reached 
signifying an ‘end of test’ criterion of < 25 ml over one second. There must be no 
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slowing down or malingering during the expiration as both have been shown to 
underestimate expired volume9. Maximum encouragement is given throughout the test, 
as sub-maximal efforts have been found to lead to spuriously high values10. An 
incorrectly inserted mouthpiece may lead to a sub-maximum effort therefore it is 
important that the patient has inserted the mouthpiece properly to ensure the expiratory 
volume is expelled smoothly and without obstruction by the tongue or false teeth. The 
patient is encouraged to rest between successive trials, as the technical acceptability of 
each manoeuvre is appraised. At least three forced manoeuvres of acceptable technical 
quality are required from any spirometry test session. Tables detailing technical 
acceptability and test reproducibility from forced expiratory manoeuvres can be found 
in appendix B. Table 4.2 outlines the procedure required to produce an accurate 
spirometry measurement. 
TABLE 4.2 PROCEDURES FOR RECORDING A SPIROMETRY 
MEASUREMENT 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Instruct and demonstrate the test to the subject, to include 
correct posture with head slightly elevated 
2 
Attach nose clip, place mouthpiece in mouth and close 
lips around the mouthpiece 
3 
Inhale completely and rapidly with a pause of <1 s at a 
full lung capacity 
4 
Exhale maximally until no more air can be expelled while 
maintaining an upright posture 
5 Repeat instructions as necessary, coaching vigorously 
6 Repeat for a minimum of three manoeuvres 
7 
Check test repeatability and perform more manoeuvres as 
necessary, no more than eight are usually required 
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4.6  MEASUREMENT VARIABILTY 
To provide a spirometry result for interpretation that is an accurate reflection of an 
individual’s lung function at the time of testing, involves an understanding not only of 
the limitations of the measurement but the factors that combine to make the 
measurement variable. A Combination of both technical and biological factors are 
responsible for most of the variability associated with spirometry. Technical factors can 
be controlled somewhat by following a quality assurance program that involves 
attention to calibration and instrument control checks.  
Biological variability has been shown to be greater when spirometry measurements are 
made weeks and months apart and in subjects with respiratory disease11,12. There are 
two types of biological variation, inter-individual (within-individual variation) and 
intra-individual (between-individual variation). An understanding of the role that both 
sources of variation play is important when it comes to interpreting a spirometry 
measurement. The primary source of inter-individual variation was found to be 
circadian rhythm, body and neck position and a sub-maximal spirometry effort, after 
accounting for short term variations caused by disease, drugs, smoking and instrument 
errors. Both host factors such as gender, height and age, and ethnicity and 
environmental factors such as the impact of tobacco smoke, general pollution and 
socioeconomic background all contribute as sources of intra-individual variation13.  
In a large study carried out on quality control in spirometry testing in eight separate 
spirometry testing facilities14, findings demonstrated that more variability was 
attributable to using different operators than between identical spirometer devices. This 
study emphasises that training and a standardised procedure are equally important 
factors when it comes to reducing variability and improving the accuracy of a 
spirometry test. 
4.7     SPIROMETRIC PARAMETERS 
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Breathing is a passive unconscious motion in non-diseased lungs. In a cycle of 
breathing approximately 500 ml of air are moved in and out of the lungs and this is 
called tidal volume (VT). An excursion from this type of resting breathing will produce 
a volume, for example a full breath in to maximum capacity from a tidal breathing 
position is termed the inspiratory reserve volume. There are three distinct lung volumes 
and a combination of two or more volumes will produces a capacity. The measurements 
of lung volume and capacity are critical determinants of overall lung function. Figure 
4.4 shows the position of each of volume and capacity of the human respiratory system. 
A definition of each lung volume and capacity can be found in appendix C. 
 
FIGURE 4.4  LUNG VOLUME AND CAPACITIES3 
 
 
 
A single spirometry manoeuvre will produce an array of volume and capacity 
measurements. The most common spirometric parameters derived from a forced vital 
capacity manoeuvre are described below. 
4.7.1 VITAL CAPACITY (VC) AND FORCED VITAL CAPACITY (FVC) 
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  Vital Capacity (VC) is the maximum volume of air that can be exhaled (or 
inhaled) from a position of full inspiration (or full expiration). When this vital capacity 
is measured from a forced manoeuvre it is called a Forced Vital Capacity (FVC). The 
FVC can be reduced in both obstructive and restrictive ventilatory disorders. In 
obstructive lung disease mucous plugging and constriction of the airways can reduce the 
volume of air to be expired. In restrictive lung disease the distensibility of the lung 
tissue itself may be compromised resulting in an inability to move a sufficient capacity 
of air out of the lung. A reliable FVC can only be achieved when a subject can 
forcefully exhale all the air out of his or her lungs up to the point where the airways 
close, called residual volume. This is called the end of test point and corresponds to a 
position whereby less than 25 ml of air are left to exhale. 
 
4.7.2 FORCED EXPIRATORY VOLUME AT (t) SECONDS (FEVt) 
The forced expiratory volume at (t) seconds is the volume of air expired during a given 
time interval (t) from the beginning of the forced vital capacity manoeuvre. The FEVt 
can be at 0.5, 3 or 6 seconds, but the FEV at 1 second is the most widely used 
standardised parameter in lung function15. The FEV1, just like the FVC, can be reduced 
in both obstructive and restrictive airway diseases. A distinction between these two 
patterns of dysfunction can be inferred by relating the FEVt to the vital capacity and 
expressing it as a ratio FEVt/VC.  
 
 
4.7.3 RATIO OF EXPIRED VOLUME TO FLOW (FEV1/FVC) and 
(FEV1/FEV6) 
 
The FEV1/FVC ratio is the standard index for assessing and quantifying airflow 
limitation. However, this ratio naturally declines with age in adults due in part to loss of 
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elastic recoil of the lungs16. The FEV1/FEV6 ratio is relating how much volume is 
expired in the first second of a forced vital capacity manoeuvre to that expired after six 
seconds. 
 
4.7.4 FORCED AVERAGE EXPIRATORY FLOW AS A PERCENTAGE OF 
FVC (FEF 25-75%) 
 
The forced expiratory flow (FEFx-y) is the average flow rate during a given volume of 
the FVC manoeuvre. X-Y refers to the portion of the FVC for which this average flow is 
measured. FEF x-y is expressed as a percentage of the FVC. The portion of 25% to 75% 
of the capacity expired is called the maximal mid expiratory flow rate or the forced 
expiratory flow from 25% to 75% of the exhaled volume. (MMEFR or FEF 25-75%). This 
measurement encompasses flow from both the medium sized and the small airways, and 
may be a more sensitive indicator for airways obstruction in patients with normal FEV1 
and FEV1/FVC values 17.  
4.7.5 PEAK EXPIRATORY FLOW (PEF) 
A peak expiratory flow (PEF) is a measure of the initial burst of air leaving the lungs 
and during testing can be a good indicator of patient effort. It reflects the portion of air 
leaving the large airways. Table 4.4 gives a definition of the main parameters measured 
during a forced expiratory manoeuvre.  
4.7.6 FORCED EXPIRATORY TIME (FET) 
 The time taken to forcefully exhale a volume of air from a position of full 
inhalation to one of full exhalation. 
TABLE 4.3 DEFINITIONS OF SPIROMETRIC PARAMETERS 
Parameter Units Definition 
VC L The maximal volume of air exhaled from a maximal inspiration 
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FVC L The maximal volume of air exhaled with maximally forced 
effort from a maximal inspiration 
FEV1 l/s The maximal volume of air exhaled in the first second of a 
forced expiration from a position of full inspiration 
FEV6 L The maximal volume of air exhaled in the first six seconds of a 
forced expiration from a position of full inspiration 
FEV1/FVC % FEV1 expressed as a percentage of FVC 
FEV1/FEV6 % FEV1 expressed as a percentage of FEV6 
FEF25-75% l/s The mean forced expiratory flow between 25% and 75% of the 
FVC. 
PEFR l/s The maximum expiratory flow generated during a maximum 
forced expiration, starting without hesitation from the point of 
maximal lung inflation 
 
As well as producing an array of spirometric measurements, most spirometers also 
provide a graphical representation of exhaled volume. The ability to view a graphical 
representation of the manoeuvre is essential for assessing patient effort and appraising 
test acceptability. The fact that healthy lungs provide very reproducible graphs and 
diseased lungs can alter these graphs in a characteristic manner makes visual inspection 
of the overall shape of the graphs very significant for interpretation purposes. 
 
 
 
4.8 EXPIRATORY FLOW VOLUME CURVES 
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The terms graph and curve are used to describe the graphical representation of a forced 
expiratory manoeuvre. Most spirometer devices have the facility to produce a graphical 
representation of the forced expiratory manoeuvre in the form of a plot of volume 
expired over time called a Spirogram, and or, flow rate plotted against volume, called a 
flow volume curve. Tracings allow for inspection for maximal patient effort and 
manoeuvre acceptability. The availability of a flow volume curve tracing can assist in 
test interpretation due to the fact that the flow volume tracing produces a very 
characteristic shape in certain lung diseases due the physiological phenomenon of 
dynamic airway compression as discussed in chapter 3. Figure 4.5 shows the spirogram 
of a subject with healthy airways who expired maximally. Volume is displayed on the x 
vertical axis and time on the y horizontal axis. 
 
 
FIGURE 4.5  SPIROGRAM4 
 
5  
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The volume exhaled is started at time zero or at the point of full inspiration, called total 
lung capacity (TLC), and as the patient expires forcefully the tracing rises abruptly as 
air leaves the large airways and then starts to plateau off as air is squeezed from 
progressively smaller airways until a point is met where no more air can be physically 
expired, a point known as the residual volume (RV) of the lung. The initial increase 
from time zero to where the line begins to curve represents the volume of air leaving the 
large to medium airways. The line then starts to ‘shoulder’ as air is forced from the 
medium to small airways and then plateaus as the small airways empty, trapping the 
essential residual volume that keeps the lungs inflated. 
Forced vital capacity can be measured directly from the spirogram tracing by extending 
a straight line from the point where the tracing plateaus to the y axis. Where this line 
intersects the y axis is the forced vital capacity measured in litres. A measurement of 
flow in the first second FEV1 is made by extending a vertical line from 1 second on the 
time scale to touch the curve and from this point a horizontal line is extended to the y 
axis where volume can be read. The FEF 25-75% can be calculated by dividing the FVC 
volume by two and dividing this by the time required to expire the middle half of the 
FVC. 
 
 FEF 25-75% = ½ FVC/∆t Equation 4.1 
 
where ∆t = the time difference between 25% and 75% points on the curve. 
The second type of tracing produced is the flow volume curve when flow rate in litres 
per second (l/s) is plotted against volume in litres (l) up to the total volume exhaled. The 
same spirometric information contained in the spirogram also exists in the flow volume 
curve, but this type of tracings makes it easier to see the subtle changes that may occur 
in the small airways. 
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 It is also easier to see technique faults with this type of tracing. Fig 4.6 shows a typical 
flow volume curve from a subject with no airways disease. There is a rapid rise to peak 
expiratory flow as air is initially forced from the large airways, but the curve then 
descends gradually with no interruption back down to zero flow as the lungs empty. 
 
FIGURE 4.6    FLOW VOLUME CURVE5 
 
 
4.9 INTERPRETATION 
In interpreting a spirometry test, consideration is given to the quality of the 
measurement with respect to patient effort, test acceptability and test reproducibility and 
to the many different sources of variation as discussed in section 4.6. When all of these 
factors have been taken into account the work of interpreting whether a given set of 
spirometry results are ‘normal’ or ‘abnormal’ begins with a comparison to reference 
values based on a population of ‘healthy’ subjects who had performed spirometry 
testing under similar conditions. These reference equations are usually pre-programmed 
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into the spirometer’s microprocessor and are easily accessible. There are wide choices 
of reference equations available, but differences in interpretation using different 
reference equations have been documented, highlighting the need to choose a reference 
set that is compatible with the population being tested18. Guidelines on lung function 
interpretation do not recommend any specific set of equations for use in Europe but do 
suggest the need for a new updated set of equations19. Reference equations are an 
important element of spirometry testing because without them interpretation would be 
very difficult. The following section provides some background information as to how 
these reference values are produced. 
 
4.9.1 REFERENCE EQUATIONS 
Stature and age play important roles in the establishment of spirometric 
reference equations. Stature can be used to empirically scale lung volumes and 
ventilatory flows and age has been shown to have a linear relationship with decline in 
lung function20. The development of the lung does not take place uniformly with stature, 
and differs between genders; females have on average smaller lungs and larger airways 
than men of comparable size21. In childhood lung growth reflects the normal body 
growth which continues up to the age of puberty. During puberty which occurs at 
approximately age 12 years in girls and age 14 years in boys there is a natural growth 
spurt after which a plateau occurs in lung function followed by an age-related decline22. 
This rate of decline is related not only to body changes but is also influenced somewhat 
by environmental factors23. The decline observed in lung function can begin during the 
plateau phase after puberty and has shown to occur earlier in smokers than in non-
smokers 24. 
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In respiratory medicine, assessment of lung function and grading of severity of lung 
disease requires accurate interpretation of the various lung function parameters. This 
interpretation process requires knowledge of what constitutes a ‘normal’ lung function 
measurement and a ‘normal’ level of decline. Normal in this context is taken to be a 
particular circumstance that does not exceed certain limits or does not deviate from an 
average or standard established for a group, class or species25. To aid in the 
interpretation of measured data, lung function analysis relies on mathematical models 
called regression equations from which reference or normal values are calculated.  
Interpretation involves relating a measured value to a reference value in order to 
determine if the result falls within a predefined range of normality. One such method is 
to compare a new measurement with a previously recorded baseline measurement. This 
technique is only practical in a situation where serial measurements are recorded 
routinely for example in an occupational screening program. More commonly, 
measured data are compared with average values from a representative population for 
which a reference range has been pre-determined by statistical analysis. A reference 
population in the context of lung function is a group of healthy individuals without 
relevant disease from which multiple regression equations have been statistically 
determined and which take into account the variables that determine the reference 
equation. In order to secure an accurate comparison the reference set chosen must be 
comparable to the patient population in terms of both biological and analytical 
variability. 
 Measurement of lung function is subject to large variation and age, stature, sex and 
ethnicity in reference equations have been shown to only account for some 40-50 
percent of this variability26. In an effort to minimise the many sources of variability that 
exist in lung function, selection of appropriate reference sets that fit the population 
being tested in terms of both biological variability and analytical compatibility is 
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required. Both the European and the American Respiratory Societies have published 
detailed recommendations on the procedures and techniques of lung function27 which 
have been recently been updated. These together with the host values are the factors to 
be considered when selecting a reference set. 
Studies designed to produce reference equations can be described as cross-sectional or 
longitudinal. In a cross-sectional study, each participant is examined once at a single 
point or period in time. In a longitudinal study, the participant is examined at pre-
defined periods of time. Most lung function reference equations have come from an 
amalgamation of cross sectional studies from many research groups and are subject to 
the ‘cohort effect’. The cohort effect describes the changes that may take place in the 
characteristics of a population such as a change in nutrition, environmental conditions, 
and other such factors which may have evolved from when data were first collected.  
When data have been collected from a reference population they are subjected to 
statistical analysis in order to generate a reference value and reference range for a 
specific spirometry or lung function parameter. For each parameter measured in the 
reference population, an average value is calculated and a measure of the variability 
around the average is given. Average and variability are statistical terms that can be 
described using a ‘normal’ or Gaussian distribution. In a normal distribution, the 
average measure is called the mean and the measure of the variability is called the 
standard deviation (SD). 
 
4.9.2 DEFINING NORMALITY 
Pulmonary function variables can be described in terms of a Gaussian distribution 
where the mean and the standard deviation determine the range of normality. In a 
normal distribution the mean is represented by the 50% line, half of the observations are 
below the predicted and half above the predicted. Figure 4.7 shows a Gaussian 
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distribution which applies the empirical rule stating that 68% of the observations fall 
within ±1 standard deviation of the mean, 95% of the observations fall within ± 2 
standard deviations of the mean and 99.7% of the observations fall within ± 3 standard 
deviations of the mean. Each standard deviation represents the probability that a single 
measured value will fall within a certain distance from the mean.  
 
FIGURE  4.7  GAUSSIAN DISTRIBUTION6 
 
 
A method of determining how far a result is from its predicted value is to express it in 
terms of the number of standard deviations the result is from the predicted. This is 
called the residual standard deviation (RSD).  
In figure 4.7, one SD from the predicted value represents 68% and two SD represents 
96%. In numerical terms one SD either side of the predicted line is -1.64.RSD or +1.64 
RSD. The addition or subtraction of 1.64.RSD from the mean predicted value results in 
an upper or lower limit of normality 28. The addition of 1.64.RSD from the predicted 
value will give the upper limit of normal (ULN) the subtraction of 1.64 RSD from the 
predicted value will give the lower limit of normal (LLN). In 95% of individuals RSD is 
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less than 1.64 times the RSD and this is called the 95th percentile. In 5% of individuals 
the RSD is less than -1.64.RSD, this is called the 5th percentile.  
The area between -1.64.RSD and +1.64.RSD in a Gaussian distribution comprises 90% 
of the population. 1.64. RSD is also referred to as the limit of normality. By defining the 
LLN as 1.64.RSD below the predicted line we are accepting a false positive rate of 5%. 
 A spirometry result that deviates from the expected value by greater than 1.64 times the 
RSD is taken to indicate that the spirometry measurement is abnormal, and this will be 
true in 95% of cases but may be an outlier in 5% of cases in individuals with healthy 
lungs.  
 
4.9.3 DEFINING AIRFLOW OBSTRUCTION USING LOWER LIMITS OF 
NORMAL (LLN) 
 
 Current recommendations on the standardisation of lung function endorse the 
use of limits of normality to accurately interpret lung function29. When defining airflow 
obstruction the use of lower limits of normal (LLN) can be used. All reference 
equations have pre-defined upper and lower limits of normal. In spirometry testing if a 
parameter is below its pre-defined lower limit of normal it is said to be an ‘abnormal’ 
finding.   
In terms of airways obstruction, as mentioned in section 4.7.3, the FEV1/FVC ratio is 
the standard index for assessing and quantifying airflow limitation. However current 
practice is to have what is called a fixed limit or a direct comparison of a measured 
value against its reference value to obtain a percentage predicted. An example of the use 
of fixed limits is the definition of an FEV1 of 80% predicted or an airflow ratio 
FEV1/FVC >70% which are often used to define normality30. Fixed limits however have 
been found to be scientifically unfounded especially when applied to extremes of age 
and height and so tend to increase the likelihood of interpretative errors31. Because the 
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FEV1/FVC ratio decreases physiologically with age, the use of fixed limits may result in 
many false positive diagnoses in older subjects. The joint ATS/ERS guidelines on 
interpretation published in 2005 define an obstructive ventilatory abnormality as a 
reduced FEV1/VC ratio below the 5th percentile of the predicted value. They also 
acknowledge that early obstructive changes can be seen in the FEF 25-75% parameter but 
that this parameter is not specific for small airways disease in individual subjects.32 
 
4.10  SUMMARY 
This chapter introduced the technical elements involved in spirometry testing and 
underlined the importance of achieving a spirometry manoeuvre that is both technically 
acceptable and reproducible. A section on reference equations and lower limits of 
normal serve to introduce the method in which spirometry values were used to detect 
the presence of airways obstruction in this thesis. 
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CHAPTER  5.  LITERATURE REVIEW 
 
5.1 INTRODUCTION 
This chapter sets out to provide a brief chronology and commentary of previous studies 
pertaining to the use of the forced expiratory volume at six seconds (FEV6) as a 
surrogate for the forced expiratory volume (FVC) in lung function testing. The 
measurement of a forced vital capacity (FVC) coupled with the expression of this 
capacity as a function of time, the forced expiratory volume in one second (FEV1) and 
their ratio FEV1/FVC, are the cornerstone parameters for spirometry measurement and 
interpretation. Definition of these FVC parameters by Tiffenau and Pinelli1 in the late 
1940s has firmly endured in spirometric testing despite six decades of medical research 
and technological advances. 
The undeniable importance of the spirometric ratio FEV1/FVC as a capable independent 
predictor of morbidity due to chronic obstructive pulmonary disease (COPD) and also 
mortality due to cardiovascular disease and lung cancer coupled with the increase of 
lung disease worldwide has led to growing support of spirometry as a major player in 
early diagnosis of lung diseases in particular COPD 2.  
 
5.2 BACKGROUND 
The accuracy and reproducibility of a spirometry measurement is dependant on 
equipment functioning properly, on the physiologist’s training and motivation, and on 
the subject’s test performance3. In an effort to reduce variability and hence improve 
accuracy, guidelines on spirometry testing were first published in the early 1980s by 
Thoracic Societies on both sides of the Atlantic. More recently joint guidelines issued 
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by the European Respiratory Society and the American Thoracic Society have provided 
a standardized approach to spirometry testing and interpretation4.  
To obtain a spirometry measurement that is technically acceptable certain criteria must 
be adhered to. One such criterion refers to when a forced expiratory effort has reached 
its natural end. Technically this criterion is satisfied when a subject’s expired breath 
shows no volume change (<25ml) in ≥1 second. In practical terms the end of test 
criterion has proven to be the most difficult and demanding for patients. In the clinical 
setting it is not unusual to have patients with prolonged expiratory times that extend 
beyond 10 seconds. This inevitably results in significant strain and discomfort for the 
patient as they are frequently encouraged to continue expiring until the end of test 
criterion is satisfied. In response to the need for an alternative end of test criterion, 
interest in a forced expiratory manoeuvre of a duration that could be easily attained by 
the majority of adults was investigated. 
 
5.3 STUDIES INTO AN ALTERNATIVE END OF TEST POINT (FEV6) 
The catalyst for research into an FVC manoeuvre of fixed duration came in the form of 
FEV6 as proposed by Glindmeyer et al.5 in 1987. In an effort to ascertain test 
reproducibility in a large sample of patients undergoing spirometry testing it was found 
that an expiration time of 6.64 seconds was more than adequate to discern an acceptable 
and reproducible test result. Although this finding demonstrated that a truncated FVC 
manoeuvre of six second duration, FEV6, reflected sufficient time to obtain test 
reproducibility, interpretation of spirometry results using this new parameter awaited 
the publication of up-to-date reference equations and lower limits of normal for a wide 
range of spirometry indices to include FEV6 and its ratio FEV1/FEV6. 
This finding seemed very promising as it offered the possibility of a shorter forced 
expiratory manoeuvre that fitted the criteria for an acceptable and reproducible test. In 
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theory this shortened manoeuvre would be less distressing for patients who have long 
expiratory times, i.e. those with obstructive airways disease and elderly patients.  
In the United States a study called the National Health and Nutrition Examination 
Survey (NHANES) published its third set of findings6 in 1994. This survey was 
designed to obtain nationally representative information on the health and nutrition 
status of a US population through interview and physical examinations. Participants of 
this survey underwent spirometry testing to assess their lung function status. Utilizing 
spirometric data collected by this survey from life-long non-smokers aged 8-80 years 
with no history of lung disease, a group of researchers, Hankinson et al.7, created and 
published spirometric reference equations and lower limits of normal for FVC and 
included  for the first time equations for the shorter spirometry manoeuvre FEV6. 
Both the NHANES III and another similar large American multi-centre survey, the 
Lung Health Survey (LHS)8, conducted at the same time, drew similar conclusions from 
their data. Both groups acknowledged spirometry as being effective in identifying mild 
airways obstruction in their participants who smoked, many of whom had previously 
denied any chest symptoms on interview. A statement documenting the importance of 
spirometry in detecting airways obstruction in asymptomatic adults was made. In 
response a subgroup known as the National Lung Health Education Program (NLHEP)9 
was established to evaluate the role of spirometry testing as a means of assessing lung 
disease.  This re-evaluation of the role of spirometry in light of previous research led the 
NLHEP group to conclude that, coupled with the appropriate reference equations, 
Glindmeyer’s proposal of FEV6 as a possible surrogate to FVC to detect early lung 
disease warranted further research. The need to advocate spirometry as a screening test 
in the primary care setting was the rationale behind their support for this shorter FVC 
manoeuvre.  A handheld spirometer with electronic quality control statements guiding 
the operator in obtaining accurate results, coupled with a shorter test manoeuvre would 
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make spirometry a more attractive tool in screening. Following from this a number of 
studies were conducted with the common aim of investigating the credibility of FEV6 as 
an alternative to FVC in detecting abnormal spirometry.  
For FEV6 and FEV1/FEV6 to have any diagnostic status, a statistical evaluation of the 
ability of this new parameter to differentiate normal from abnormal spirometry results- 
as defined by the statistical terms sensitivity, specificity, and positive predictive value 
(PPV) and negative predictive value (NPV) needed to be assessed. A section detailing 
the statistical methods used in this research and in other papers cited in this chapter is 
dealt with in chapter 6. 
Swanney et al.10 were the first researchers to analyse and publish findings on the new 
FEV6 parameter. This group retrospectively analysed spirometry data from 502 patients 
attending a New Zealand hospital. They found the new FEV1/FEV6 ratio to be a good 
substitute for the traditional FEV1/FVC ratio in its ability to detect abnormal lung 
function. As part of this analysis, Swanney et al. directly compared FEV6 to FVC and in 
doing so found FEV6 to be less variable and more reproducible. 
The ability of the FEV6 parameter to accurately diagnose abnormal spirometry will 
depend on the prevalence of this abnormality in the population being tested. In 
Swanney’s research population approximately two thirds of the subjects had 
documented airways obstruction i.e. the prevalence of obstruction was 65.6% leading to 
the high positive predictive value (PPV) of 98.6% experienced by that research group. 
This meant that a patient with airways obstruction had been correctly diagnosed with 
airways obstruction using FEV1/FEV6, 98.6% of the time.  
Results from that study looked promising for FEV6, but as the authors pointed out in 
their discussion, more work was required by other researchers using larger numbers of 
subjects in a population with a different prevalence of obstruction, to confirm their 
findings.  
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This call was answered by Vandervoode et al.11 who analysed spirometry data from a 
much larger patient group (11,676) with an overall prevalence of obstruction of 39.9%. 
Results in terms of both sensitivity and specificity for FEV6 were very similar to the 
previous researchers. A lower prevalence of obstruction in this group of subjects 
produced a lower PPV (89.8% vs. 98.6%), whereas the negative predictive value 
(NPV), in which a subject with normal lung function was correctly diagnosed as normal 
spirometry, using the new ratio was higher (96.0% vs. 91.1%). Vandevoorde and co- 
workers’ research added more weight to the argument that FEV6 could be substituted 
for FVC without affecting the test’s ability to detect abnormal spirometry.  
Following this, in a study of 5,114 Turkish patients who underwent spirometry as part 
of their lung function assessment, Demir et al12 found FEV6 to underestimate FVC and 
so produce relatively low sensitivity (86%). They found this to be particularly evident in 
cases where the forced vital capacity measurement was more than 1 litre greater than the 
forced expiratory volume after six seconds. The reduced sensitivity experienced by this 
research group was not surprising given the ‘fixed cut off ‘method employed to classify 
airways obstruction. In the study a spirometry result producing an FEV1/FVC or an 
FEV1/FEV6 ratio below a fixed 70% was deemed abnormal. In using the same fixed cut 
off point for both ratios, this group failed to consider that both ratios not only decline 
with age but also with forced expiratory time13. To properly compare FEV1/FVC with 
FEV1/FEV6 in the context of defining airways obstruction using a fixed cut-off point, an 
FEV1/FEV6 which best predicted an FEV1/FVC ratio of 0.70 would need to be 
calculated using appropriate statistics. 
This was duly researched in another study by Vandervoode et al. on the role of FEV6 
with the purpose of determining fixed cut off points for FEV1/FEV6 and FEV6 in the 
detection of abnormal spirometry14. As traditional criteria for detecting abnormal 
spirometry involves the use of fixed cut off points15 this study unlike that of Demir et al. 
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sought to provide fixed cut of points specifically for the FEV6 parameter. Results from 
this study showed that FEV1/FEV6 <73% can be used as a valid alternative to 
FEV1/FVC <70% in the detection of airways obstruction. The authors rightly caution 
the use of fixed cut off points in spirometry interpretation, as this practice has been 
found to be statistically unsound particularly in the elderly age group due the fact that 
they fail to take into account the natural age related decline in the FEV1/FVC and 
FEV1/FEV6 parameter, leading to the potential for misclassification16. However, as this 
group also pointed out there are no specific European spirometric reference equations 
and lower limits of normal for FEV1/FVC and FEV1/FEV6 covering all age ranges. Until 
such reference equations are established the practice of using fixed cut off points will 
remain widespread. 
The next major study on FEV6 to be published reviewed its role in detecting abnormal 
spirometry in the workplace setting. Alkpinae et al.17 hypothesized that the FEV6 
parameter would, in this setting, result in a ‘low misclassification’ rate for detecting 
airways obstruction, compared to the traditional FVC parameter. Spirometry results for 
1,143 workers from four workplace settings were analyzed using appropriate reference 
equations and lower limits of normal for both parameters.  
The authors concluded that FEV6 could be used as a reliable substitute for FVC in 
detecting abnormal spirometry in the workplace setting. Results showed that only 3.8% 
of workers in this study were classified differently by the two techniques thus yielding a 
high sensitivity and low misclassification rate. This research was a departure from 
previous studies looking specifically at the diagnostic ability of FEV6 in the clinical 
setting. In the workplace setting there is perhaps a greater reliance on good quality 
spirometric results for accurate interpretation from a medico-legal standpoint as the 
potential for developing lung disease from workplace exposures may exist in certain 
circumstances.  
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In a study published by Hansen et al.18 the use of FEV6 in detecting airways obstruction 
was critically analyzed. Spirometry data from the NHANES III survey was used in this 
retrospective study. By substituting FVC with FEV6 the authors found that the 
sensitivity of a spirometry test to screen for obstruction was reduced, particularly in 
elderly subjects and subjects with mild airways obstruction as defined by the FEV1/FVC 
ratio. This prompted the authors to call into question the utility of FEV6 in producing an 
accurate diagnosis in these two specific groups. 
 In response to the recommendation from the NHLEP advocating spirometry as a 
screening test in primary care settings, Gleeson et al.19 published a study on the 
accuracy of the FEV6 in detecting abnormal spirometry at a community hospital. This 
study assessed the concordance of FEV1/FVC and FEV1/FEV6 using NHANES 
reference equations and their own routinely used reference equations. Better sensitivity 
for detecting abnormal spirometry was found in their study group using the NHANES 
equations but moderate specificity was found when using their own reference equations. 
This study cautioned the use of FEV6-based interpretation of spirometry results in a 
primary care setting irrespective of the reference equations chosen, citing the 
importance of motivated trained professionals in administering spirometry in an effort 
to curtail poor quality results. 
The agreement between FEV1/FEV6 and FEV1/FVC in an elderly population was 
further investigated by Melby et al.20. This group analysed spirometric data from a large 
sample of Norwegian subjects over 60 years of age. They reported the mean difference 
in both ratios, regardless of gender to be 2.7%. On further analysis they found this 
difference to be more pronounced in smokers and those with a reduced FEV1/FVC ratio. 
In response to previous research on fixed cut -off points this group sought to create 
fixed cut -off points specifically for their elderly study group. A fixed cut-off point of 
73% for FEV1/FEV6 was found to be the best substitute for an FEV1/FVC cut-off point 
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of 70%. This mirrored the results obtained for fixed cut-off points by the Vandervoode 
et al. group. The authors concluded that the FEV1/FEV6 ratio was a good substitute for 
FEV1/FVC in an elderly population. 
 Reference equations are paramount in allowing investigators to determine the 
diagnostic accuracy of the shortened FEV6 manoeuvre. However currently the only 
reference equations available for a wide age range (8-80) years that include the shorter 
FEV6 parameter are those published by Hankinson from NHANES III data. The choice 
of reference equations in spirometry testing has been shown to have a significant effect 
on the interpretation21. In a recent consensus22 from experts on both sides of the Atlantic 
in an effort to standardize interpretation of lung function, choosing reference equations 
that accurately match the population being studied was advocated, while at the same 
time acknowledging the lack of widespread spirometric reference equations that take 
into account the rate of decline of lung function with age. In response to this dearth of 
appropriate spirometric equations for elderly subjects, studies have been published in 
recent years giving more equations and lower limits of normal for subjects over 60 
years 23, 24. 
In particular Garcia-Rio25 published reference equation for European males and females 
in the age range 65-85 years and included for the first time reference equations and 
lower limits of normal for the FEV6 and FEV1/FEV6 for European elderly adults. The 
availability of these equations provided the means for investigating the agreement 
between FEV6 and FVC in diagnosing airways obstruction in patients over the age of 65 
years in this thesis. The most recent addition to the library of FEV6 reference equations 
has been published by a group of New Zealand researchers26 for a New Zealand 
population of European origin aged 25-75 years.  
Updated European spirometric reference equations for a widespread age range to 
include reference equations and lower limits of normal for FEV6 parameters will lead 
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the way to much needed research into the utility of the FEV6 parameter in spirometric 
detection of abnormality and in particular into early screening at a primary care level. 
 
 
5.4 SUMMARY 
The majority of research publications to date show that FEV6 is a suitable alternative to 
the traditional FVC manoeuvre. Although the methods used to compare FEV6 to FVC in 
the research studies outlined in this chapter are similar to this research, this study is the 
first to our knowledge to compare FEV1/FEV6 and FEV1/FVC using the Garcia-Rio 
reference equations for elderly subjects aged 65-85 years. 
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CHAPTER 6 METHODOLOGY  
 
6.1 INTRODUCTION 
This chapter gives a brief summary of the methodology used for each of the three main 
sections of this thesis. Ethics approval for this research study was sought and granted by 
the ethics committee of the Bon Secours Hospital Group and specific request to include 
the spirometry data from patients under the care of three referring consultant respiratory 
physicians was sought and granted. Spirometry was performed using the same mass 
flow- sensing spirometer (Sensor Medics Vmax 22 +Autobox V6200, Viaysis 
Healthcare), and the author of this thesis was responsible for carrying out each 
spirometry test included in this study. Equipment specification sheets are included in 
appendix D. The highest pre-bronchodilator FVC, FEV1 and FEV6 were included in the 
analysis.  
All numeric values are given as mean ± standard deviation. All of the data contained in 
this study were obtained retrospectively. Non parametric t- tests were chosen as the 
most suitable tests for evaluating the data in study 1. Statistical significance was taken 
at p < 0.05 level, and a statistically highly significant was taken as p < 0.001. Symbols 
are used to denote degrees of significance of the results tables in chapter 7. The system 
used is *, **, and *** to mean P<0.05, 0.01 and 0.001 respectively 1. 2-by-2 
contingency tables2 are the statistical method chosen as the most suitable way to display 
data in sections B and C for statistical evaluation.  
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6.2 (SECTION A) THE SPIROMETRIC FINDINGS OF SMOKERS 
COMPARED TO NON-SMOKERS 
 
As our objective in this study was to investigate the usefulness of spirometric 
parameters and in particular the new FEV6 parameters in providing an early indicator of 
dynamic airway changes in smokers we carried out a retrospective search of the 
pulmonary function database to included patients with an FEV1 and an FEV1/FVC of 
greater than 75% of predicted. This search produced n = 156 smokers (91 female,65 
male) and n = 178 non-smokers (111 female, 67 male). Smokers in this study were 
patients who smoked at the time of testing either daily or occasionally. Non-smokers 
were patients who had not smoked at all at the time of testing3. We chose the following 
demographic variables and spirometric parameters to compare both groups.  
 
Demographics variables:     
Age (Years)         
Height (cm)       
Weight (kg)        
Body Mass Index (kg/m2)     
Gender     
Spirometric parameters 
FVC  
FEV6 
FEV1/FVC 
FEV1/FEV6 
FEF25-75% 
FET  
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The spirometric parameters obtained represent the highest pre-bronchodilator from tests 
containing at least three spirometry manoeuvres. Each spirometry manoeuvre was 
assessed according to recently published guidelines on standardisation of spirometry 
testing4 and passed as acceptable and reproducible. 
Data are presented as mean percent predicted ± standard deviation and statistical 
significance was determined using non-parametric two tailed t-tests (Table 7.1). 
Data from the smoking group were sorted by the number of cigarettes smoked daily 
Two groups were established, Group 1 consisted of smokers with a self-reported 
consumption rate of less than 20 cigarettes per day (n = 67) and Group 2 greater than 20 
cigarettes per day (n = 89). Data are presented as mean percent predicted ± standard 
deviation and statistical significance was determined using non-parametric two tailed t-
tests (Table 7.2) 
Data were sorted by gender to compare male smokers (n = 65) to male non-smokers  
(n = 67) and female smokers (n = 91) to female non-smokers (n = 111). Results are 
presented as mean percent predicted ± standard deviation and statistical significance 
was determined using non-parametric two tailed t-tests (Tables 7.3 and 7.4) 
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6.3 (SECTION B) A COMPARISON OF FEV1/FEV6 WITH FEV1/FVC IN 
DIAGNOSING AIRWAYS OBSTRUCTION  
 
A retrospective search of the pulmonary function database over a period of 4 months 
resulted in n = 171 patients, female (n = 87), male (n = 84). Only patients with 
spirometry data meeting the acceptability and reproducibility criteria set out in table 6.1 
were included in this study. 
TABLE 6.1 INCLUSION CRITERIA 
Abrupt start of test with a  back extrapolated 
volume < 150 ml of FVC 
No evidence of cough 
No evidence of glottis closure 
A Forced Expiratory Time (FET) of at least 
6 seconds duration 
Three spirometry trials with each FEV1 and 
FVC within 150 ml of each other 
Evidence of a satisfactory end of test (EOT) 
criterion (< 25 ml expired over 1 second)  
 
Applying the above criteria resulted in 72 patients (33 female, 39 male) being excluded 
from the study. Subject demographics, specific reasons for exclusion and spirometry 
results of the excluded group are given in appendix E. 
Of the remaining 99 subjects (55 female, 44 male) we calculated a mean and standard 
deviation on the following highest pre-bronchodilator measured spirometric parameters 
FVC, FEV6, FEV1, FEV1/FVC, FEV1/FEV6, FEF25-75%, FET and the following subject 
variables, age, height, gender and body mass index. (Chapter 7, Tables 7.5 and 7.6).  
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An inter-subject coefficient of variation (CoV) was calculated for FEV1/FVC and 
FEV1/FEV6, by dividing the mean standard deviation of the ratio by the mean of the 
ratio and multiplying by 100 to obtain the percentage CoV.  
 
STUDY B1 
The data were then sorted by age into four categories.  
Category 1 20-29 years (n = 4) 
Category 2  30-49 years (n = 24) 
Category 3 50-69 years (n = 49)  
Category 4 70-89 years (n = 22).  
The mean measured FEV1/FVC and mean measured FEV1/FEV6 were compared for 
each category. (Table 7.7) 
 
STUDY B2 
Data were then sorted by the degree of airways patency as defined by the mean 
measured FEV1/FVC ratio, into four groups. 
Group 1 FEV1/FVC > 80 
2 FEV1/FVC 70-80 
3 FEV1/FVC 50-69 
4 FEV1/FVC < 50  
 
The mean measured FEV1/FVC and mean measured FEV1/FEV6 were compared for 
each category. (Table 7.8). 
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STUDY B3 
In order to assess the diagnostic ability of FEV1/FEV6 in identifying airways obstruction 
we compared the measured FEV1/FVC and FEV1/FEV6 to their corresponding lower 
limit of normal values. Lower limit of normal equations were obtained from the 
NHANES III reference set 2 are given in appendix F. If the measured value of the ratio 
was higher than its corresponding LLN value, the test was categorised as not obstructed. 
If the measured value was less than its LLN, the test was categorised as obstructed. To 
determine the sensitivity and specificity of the FEV1/FEV6 ratio in diagnosing airways 
obstruction a 2*2 contingency table was constructed. A sample contingency table is 
shown in table 6.2. The terms positive and negative are used to refer to the presence or 
absence of airways obstruction. 
 
TABLE 6.2 SAMPLE CONTINGENCY TABLE 
 
 
 
TP = True positive  (FEV1/FVC < LLN and FEV1/FEV6 < LLN) 
 TN = True negative (FEV1/FVC > LLN and FEV1/FEV6 > LLN) 
FP= False positive  (FEV1/FVC > LLN and FEV1/FEV6 < LLN) 
 FN =False negative (FEV1/FVC < LLN and FEV1/FEV6 > LLN) 
 
Sensitivity, Specificity, positive predictive value (PPV) and negative predictive value 
(NPV) were calculated following the Bland and Altman definitions 5 
 
 
 
TP FP 
 FN TN 
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Sensitivity = TP/ (TP+FN)      Equation 6.1 
 
 
Specificity = TN/ (FP+TN)      Equation 6.2   
 
 
PPV = Sensitivity * prevalence 
          Sensitivity*(1-Specificity)*(1-prevalence)    Equation 6.3 
 
 
NPV= Specificity* (1- prevalence) 
 (1-sensitivity)*prevalence+ specificity*(1-prevalence) Equation 6.4 
 
 
Values that fall into the FP and FN categories are referred to as discordant cases. The 
subject demographics and mean measured FEV1/FVC and FEV1/FEV6 ratios of 
discordant cases together with their LLN values were calculated (Table 7.9). 
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6.4 (SECTION C) FEV1/FEV6 AS A SUBSTITUTE FOR FEV1/FVC IN A 
SUBGROUP OF ELDERLY PATIENTS USING TWO SETS OF 
REFERENCE EQUATIONS 
 
A retrospective search of the pulmonary function database was conducted for subjects 
aged 65-85 years who could exhale for at least six seconds and who met the clinical 
guideline criteria for this, resulted in n = 68 patients (35 female,33 male). Over the 
course of this research project our pulmonary function database was upgraded6 to allow 
us to input a specific search pattern to include only those subjects meeting the inclusion 
criteria set out in (Table 6.1) 
Mean and standard deviation values were obtained for age, height and FET (table 7.11) 
and  FVC, FEV6, FEV1, FEV1/FVC, FEV1/FEV6, and FET (Table 7.12) 
We compared FEV1/FVC and FEV1/FEV6 to the lower limits of normal from the 
NHANES III spirometry reference set7, and constructed a contingency table as 
described in section 6.3. This was repeated using reference equations and lower limits 
of normal from the Garcia-Rio spirometry reference set8 (Table 7.13 and 7.14), 
appendix G. 
 
6.5 SUMMARY 
This chapter provided a brief description of the methodology used for the three results 
sections included in chapter 7.  
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7 RESULTS AND DISCUSSION 
 
7.1 INTRODUCTION 
This chapter consists of results and discussion relating to the three main experiments to 
achieve the aims set out in Chapter 1.We have subdivided our results into three sections, 
Sections A, B and C. Section B is subdivided further into B1, B2 and B3. The heading 
of each section is as follows. 
 
Section A:  
The spirometric findings of smokers compared to non-smokers.  
Section B:  
1. The effects of age on FEV1/FVC and FEV1/FEV6 
2. The effects of the degree of airway patency on FEV1/FVC and FEV1/FEV6  
3. Comparison of the FEV1/FEV6 ratio to the FEV1/FVC ratio in its ability to 
accurately diagnosis airways obstruction.  
Section C:  
Comparison of two different sets of FEV6 reference equations and the ability of each set 
to detect airways obstruction in a group of elderly patients 
 
Each section begins with a brief summary of the aim of the study, a table(s) of results, a 
discussion of results, and a brief summary. The methodology and statistical method 
used for each study is outlined in Chapter 6. 
 
 
 
 
 
 
95
SECTION A 
 
7.2 THE SPIROMETRIC FINDINGS OF SMOKERS COMPARED TO NON-
SMOKERS  
 
7.2.1 AIM OF STUDY 
The aim of this study is to investigate whether a significant difference exists in the 
spirometric parameters of smokers compared to non-smokers. Among the parameters 
are the FEV6 and the FEV1/FEV6 ratio. Smoking has been found to be a strong 
independent risk factor for the development of chronic obstructive pulmonary disease 
(COPD), and a high proportion of COPD patients are smokers1. Cigarette smoking in 
particular has been documented in numerous cross-sectional and longitudinal studies to 
be an important determinant of the level of lung function reduction.2,3,4. However, other 
factors increase the likelihood of developing COPD and include passive exposure to 
tobacco smoke5, air pollution6, history of childhood respiratory infections7, presence of 
airway hyper-responsiveness8, alpha-1 antitrypsin deficiency9, and occupational 
inhalation hazards10. Spirometry testing has the ability to identify mild airflow 
abnormalities in asymptomatic smokers. In particular, a reduction in the FEV1/FVC 
ratio has been shown to be a strong predictor for rapid progression of COPD11 in 
subjects with a ‘normal’ FEV112. All subjects in this study had an FEV1/FVC and an 
FEV1 of greater than 75% predicted. 
In this study we hypothesised that by including data from patients with ‘normal’ 
spirometry, subtle differences in lung function between smokers and non-smokers may 
be detected. In particular we chose to investigate if the FEV6 parameter could provide 
any additional information regarding early airway changes in subjects ‘at risk’ of 
developing COPD, our smoking group. We also looked at the possibility of a gender 
difference in susceptibility to smoking. The values presented in tables 7.1, 7.2, 7.3 and 
7.4 are mean percent-predicted ( standard deviation) for smokers and non-smokers. 
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7.2.2 RESULTS 
In this study the results presented in table 7.1 show the mean age of the non-smoking 
group to be 54.4 years (SD 16.3) and BMI 27.2 (SD 5.1),with the mean age of the 
smoking group 53.6 (13.7) years and mean BMI  26.9 (5.1). The mean percent predicted 
FVC of non-smokers is 92% (SD 12.1) and in smokers, this was found to be 94% (SD 
10.6). The mean FEV6 of the non smoking group is 93% (SD 12.3), and in the smoking 
group is 94% (SD 10.3). The FEV1/FEV6 ratio of non-smokers yielded the same mean 
% predicted as the FEV1/FVC, 99%. However, the FEV1/FEV6 standard deviation 
value was slightly lower 6.08 compared to a SD of 7.4 for the FEV1/FVC ratio. In 
smokers both FEV1/FVC and FEV1/FEV6 had a mean percent predicted of 96% but 
again the FEV1/FEV6 ratio produced a lower SD of 6.0 compared to a SD of 7.6 for 
FEV1/FVC in this group. The mean forced expiratory time of smokers was 9.4 (2.5) 
seconds and non-smokers 8.5 (2.2) seconds.  
TABLE 7.1   DEMOGRAPHICS AND SPIROMETRY DATA OF NON-
SMOKERS AND SMOKERS 
Parameter Non- Smokers n= 178 
(111 female) 
Smokers n=156 
 (91 female) 
 
P value 
 
FVC  92.312.1 93.910.6  0.218 
 
FEV6 93.112.3 93.910.3  0.545 
 
FEV1/FVC 99.87.4 96.27.6 0.0001*** 
FEV1/FEV6 99.16.1 96.36.0 0.0001*** 
FET 
(seconds) 
8.52.2 9.42.5 0.0007*** 
FEF25-75% 93.228.2 82.526.2 0.0004*** 
AGE (years) 54.416.3 53.613.7 0.648 
 
BMI (kg m2) 27.2  5.1 26.9  5.1  0.590 
Values presented above are mean % predicted  SD 
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In Table 7.2 our results show that among our total smoking group 67 patients smoked 
on average less than twenty cigarettes a day, and 89 patients admitted smoking greater 
than 20 cigarettes a day. All mean percent predicted spirometric values are lower in the 
> 20 per day group compared to the < 20 per day group, but the statistical difference 
was not significant. 
 Smokers who consumed > 20 cigarettes per day were on average 4 years older 55(13.3) 
years compared to an average age of 51(14.2) years for patients with a < 20 per day 
habit. 
 
TABLE 7.2  SMOKERS WITH <20 AND > 20 CIGARETTES   SMOKED/DAY 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 Smokers  
< 20/day 
(n = 67) 
Smokers 
> 20/day 
(n = 89) 
p value 
FVC 95.011.1 
 
93.110.0 
 
 
0.287 
FEV6 95.010.5 
 
93.110.0 
 
0.266 
FEV1/FVC 96.78.0 
 
95.97.3 
 
0.532 
FEV1/FEV6 97.06.1 
 
96.16.0 
 
0.590 
FEV1 92.012.2 
 
89.610.6 
 
0.193 
FEF 25-75% 85.427.4 
 
80.424.9 
 
0.244 
FET 9.42.6 
 
9.42.4 
 
0.884 
AGE 51.614.1 
 
55.213.3 
 
0.109 
BMI 26.54.8 
 
27.25.7 
 
0.386 
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In Table 7.3 our results show a similar number of male smokers (n = 67) and male non-
smokers (n = 65). Male smokers were on average slightly older, 51(12.8) years, than 
male non-smokers, 48(17.0) years, and had longer forced expiratory times 9.75(2.5) 
seconds compared to 8.48(2.3) seconds. Both FEV1/FVC and FEV1/FEV6 ratios were 
significantly lower in male smokers than in male non-smokers. The mean FEF25-75% in 
male smokers was 85% (26) compared to 93% (26) for male non-smokers. 
 
TABLE 7.3  MALE SMOKERS AND NON-SMOKERS 
 
 
 
 
 
 
 
 
 
 
 
Parameter Male non-smokers n = 67 
(mean  SD) 
Male smokers n = 65 
(mean  SD) 
 
p value 
 
FVC 92.312.8 92.99.3 0.756 
FEV6 
93.312.5 93.59.2 
0.907 
FEV1/FVC 100.06.9 96.77.8 0.0115* 
FEV1/FEV6 99.05.5 96.36.3 0.0083** 
FEF25-75% 93.526.1 85.026.0 0.05 
FET 8.52.3 9.82.6 0.010** 
AGE 48.317.0 50.912.8 0.326 
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In Table 7.4 results on female smokers (n = 91) and  female non-smokers (n = 111) 
show that female smokers have mean percent predicted FEV1/FVC, FEV1/FEV6, FET 
and FEF25-75% that are lower than female non-smokers, by a statistically significant 
difference, represented by a p value < 0.05. 
 
TABLE 7.4  FEMALE SMOKERS AND NON-SMOKERS 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Female non-smokers n= 111 
(mean  SD) 
Female smokers n = 91 
(mean  SD) 
 
p value 
 
FVC 92.212.3 94.611.3 0.161 
FEV6 92.912.2 94.211.0 0.465 
FEV1/FVC 99.67.7 95.97.5 0.0007*** 
FEV1/FEV6 99.06.4 96.35.9 0.0024** 
FEF25-75% 92.929.4 80.826.0 0.003** 
FET 8.52.1 9.32.40 0.012* 
AGE 58.214.4 55.614.1 0.205 
BMI 27.6 5.4 26.5 5.6 0.157 
 
 
 
100
7.2.3 DISCUSSION   
Subjects tested were all patients referred to the pulmonary function laboratory for 
various clinical reasons. A proportion of this study group had suspected pulmonary 
disease and cannot be strictly classed as a ‘normal’ population. However the selection 
process ensured that only ‘normal’ spirometry data were included for both groups. 
Details on selection process and analysis are given in Chapter 6.  
When statistical analysis was applied to the data, in the form of the non-parametric 
student’s t-test, subject age and body mass index (BMI) were found to be comparable 
between both groups. We found no statistically significant difference between smokers 
and non-smokers in FVC and FEV6 values. The average FEV6 parameter expressed as a 
percent of predicted for both groups showed a very close agreement with its 
corresponding FVC, but did not offer any additional information regarding possible 
early signs of change in lung function in the current smoking group. Regardless of 
smoking history the FEV1/FEV6 ratio did exhibit a lower standard deviation (SD) value 
indicating that this parameter is a less variable, more definite end of test point compared 
to the FEV1/FVC ratio. 
 In a group of middle aged men and women, mean age 54(15) years having performed 
spirometry testing for various clinical reasons we found a significantly lower 
FEV1/FVC, FEV1/FEV6, FEF25-75% and FET in smokers compared to non-smokers.Both 
ratios FEV1/FVC and FEV1/FEV6 were reduced in the smoking group compared to the 
non-smoking group. From a clinical viewpoint, both smokers and non-smokers in our 
study have ratios that would be considered well ‘within normal limits’13, (Table 7.1). 
However for the same mean age (smokers 53 years, non-smokers 54 years) the smoking 
group may be beginning to exhibit an earlier decline in lung function compared to non-
smokers as shown by the FEV1/FVC, FEV1/FEV6 ratios.  
 
 
 
101
We can also see from this study that the FEV1/FEV6 ratio declines in a similar manner 
to the FEV1/FVC ratio regardless of smoking habit. This finding would suggest that 
given similar readings the shorter FEV6 manoeuvre could be used successfully as a 
surrogate for the FVC manoeuvre.  
The lower SD scores of the FEV1/FEV6 ratio also suggest that this shorter manoeuvre 
has less variability. Reducing the variability of this type of measurement may lead to a 
more accurate interpretation of the measurement and result in a lower misclassification 
rate when it comes to classifying spirometry results as normal or abnormal. 
In this study, further evidence of an earlier decline in lung function in smokers with a 
normal FEV1/FVC and FEV1/FEV6 ratio can be seen in the reduced FEF25-75%. The 
majority of studies into the effects of smoking on lung function have focused on 
FEV114,15,16. However, effects may also be revealed in other measures of lung function 
such as the FEF25-75%. This parameter is a measure of the average flow rate between 25% 
and 75% of the forced vital capacity, and flow rates from this portion of the FVC 
specifically reflect the patency of airways < 2 mm in diameter, called the peripheral 
small airways. The significance of a reduced FEF25-75% has been investigated in other 
studies and although this parameter has a wide variability (reflected in this study by a 
large SD value), it has been suggested to be an early indicator of small airways disease 
in subjects who have otherwise normal lung function as assessed by means of FEV1 and 
FEV1/FVC17. Early studies into small airways dysfunction revealed that COPD affects 
the small peripheral airways in its sub-clinical early phase18.  
The FEF25-75% parameter is significantly reduced in our smoking group, despite this 
group having ‘normal’ ratios. As airflow limitation prolongs the forced expiratory time 
(FET), the longer FET in the smoking group may reflect early closing of the peripheral 
airways and possibly the significantly reduced FEF25-75%.   
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Despite the subtle early differences seen in this study, a longitudinal study of these 
patients is warranted to properly assess if the smokers have a greater risk of a rapid 
decline in lung function heralding early COPD.  
Previous longitudinal studies documented that the FEV1/FVC ratio is a strong predictor 
for rapid progression of COPD in smokers19 and recently a study by Enright et al 
showed that the FEV1/FEV6 ratio could also predict lung function decline in adult 
smokers 20.  
Other studies into early detection of COPD through spirometry testing have included 
data on the effects of smoking consumption in the form of pack-years. In our study we 
did not have access to pack years data, but were able to record the average number of 
cigarettes each smoker admitted to smoking per day. These data are included in Table 
7.2 and our results show  no statistically significant difference in either demographic or 
spirometric parameters in the smoking group, as between those smoking on average 
greater than 20 cigarettes per day and those smoking less than 20 cigarettes per day. 
Other studies in this area have found evidence that the number of cigarettes smoked has 
a linear effect on pulmonary function level and rate of loss. In particular a cross- 
sectional analysis in the Six Cities Study21, 23 showed that in comparison to ex-smokers, 
current smokers had lower levels of lung function as measured by spirometry. The 
subjects included in our study were a mixture of male and female current smokers and 
never smokers. To investigate if gender played a role in the differences between 
smokers and non-smokers with regard to spirometry values we compared male smokers 
to male non smokers and female smokers to female non smokers using student’s t-tests 
for statistical significance, the results of which are shown  in tables 7.3 and 7.4. 
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As shown in tables 7.3 and 7.4 the same parameters, FEV1/FVC, FEV1/FEV6, FEF25-75% 
and FET  that showed a statistically significant difference in our total smokers compared 
to non-smokers group (table 7.1) also showed a statistically significant difference in our 
comparison of male smokers to non-smokers and female smokers to non-smokers.  
This finding suggests that gender did not give any additional information regarding 
subtle differences in smokers and non-smokers in our limited study group. However the 
male non-smokers were younger than the male smokers whereas the female non-
smokers were older than the female smokers and this finding may be evidence for the 
claim that women are taking up smoking at a younger age. In a study of Irish teenagers, 
researchers found that 20.7% of young teenagers actively smoke and significantly more 
females than males do so22.  
Several longitudinal studies have been published on gender differences in the 
susceptibility to cigarette smoking, but there is little clarity, as some studies show the 
reduced level of lung function associated with cigarette smoking to be greater in men 
than in women23, 24 and other studies report that women are more susceptible 25, 26.  
 
7.2.4 SUMMARY  
The initial aim of this study was to investigate if parameters from the shorter six-second 
spirometry test could provide early signs of airways obstruction heralding the beginning 
of COPD in a group of patients at risk for developing this disease due to their smoking 
habits. Our results showed that the FEV6 parameters did not provide any additional 
information to that already obtained from the traditional FVC parameters, however the 
FEV1/FEV6 ratio did decline in the same manner as the FEV1/FVC ratio in smokers 
compared to non-smokers of similar age and demographics. We also found that the 
FEV6 parameters and in particular FEV1/FEV6 ratio had a lower standard deviation than 
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the FEV1/FVC ratio, suggesting that this parameter may be a more accurate and 
reproducible measurement. 
Given this finding the shorter FEV6 manoeuvre could be an attractive shortcut to the 
traditional FVC spirometry manoeuvre. A shorter manoeuvre would reduce the burden 
of the test for those patients with prolonged forced expiratory times and in elderly 
subjects.  
 
7.2.5 HYPOSTASIS 
To further investigate if the shorter FEV6 manoeuvre could be an alternative to the 
traditional FVC manoeuvre, we compared the FEV1/FEV6 ratio to the FEV1/FVC  ratio 
in their ability to diagnose airways obstruction using reference equations with lower 
limits of normal. The results of this study are set out in section B. 
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SECTION B 
7.3 A COMPARISON OF FEV1/FEV6 WITH FEV1/FVC IN DIAGNOSING 
AIRWAYS OBSTRUCTION 
 
7.3.1 AIM OF STUDY 
The initial aim of this study was to compare the FEV1/FEV6 ratio to the traditional ‘gold 
standard’ FEV1/FVC ratio to determine its ability to detect airways obstruction. We 
compared each ratio with its corresponding lower limit of normal value which was 
taken from a reference set that included equations for both the traditional FVC and the 
‘new’ FEV6 parameters. Detailed equations and lower limits of normal used in this 
study can be found in appendix F. Using the spirometric data obtained from patients 
included in this study we were able to investigate the behaviour of both FEV1/FVC and 
FEV1/FEV6 with increasing age and decreasing airways patency. These two studies are 
presented in sections B1 and B2 respectively.  
 
7.3.2 RESULTS FROM SPIROMETRY DATA 
In order to assess the ability of the FEV1/FEV6 ratio in diagnosing airways obstruction 
we examined spirometry data from a sample of our patient population. The subject 
demographics for ninety-nine subjects included in this study are presented in table 7.5. 
Mean (SD) age was 56.3(14.6) years and the mean (SD) forced expiratory time (FET) 
for the group was 9.4(2.8) seconds. Of the total number of patients included in this 
study forty-four were male and fifty-five female. The mean (SD) Body Mass Index 
(BMI) was 26.6(5.5) and mean (SD) height was 167(9.8) cm. We also looked at 
smoking habits of the group and found that 45 were non-smokers, 46 were ex-smokers, 
and 8 were current smokers. Of the current smokers seven out eight were female. 
 
 
 
 
 
106
TABLE 7.5  SUBJECT DEMOGRAPHICS 
Subject Demographics Mean ± SD 
 
Age (years) 56.3 ± 14.6 
Age range  
 
42 -70 
 
Height (cm) 167 ±9.8 
BMI (kg/m2) 
 
26.6 ± 5.5 
 
TABLE 7.6  SPIROMETRY DATA 
Spirometry Parameter 
 
Mean ± SD 
FVC %predicted 
 
82.2 ± 16.5 
FEV6 %predicted 
 
81.7 ± 18.5 
FEV1 %predicted 
 
76.9  ±  22.5 
FEV1/FVC % 
 
91.8  ± 15.7 
FEV1/FVC measured 
 
71.4  ±  12.6 
FEV1/FEV6 % 
 
92.5  ±  11.7 
FEV1/FEV6 measured 
 
74.5 ±  9.8 
FEF25-75% predicted 
 
71.3 ±  39.8 
 
FET 9.4   ± 2.8 
Mean difference in FEV1/FVC and 
FEV1/FEV6 ratios expressed as 
measured values 
 
3.1 
Inter-subject CoV                         
 
FEV1/FVC %                               17.2%                                             
 
FEV1/FEV6 %                              12.7% 
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Spirometry data  
In table 7.6, a mean and standard deviation (SD) was calculated for each of the 
parameters. The standard deviation represents a measure of dispersion or variability in 
the data set. The higher the SD figure the greater the spread of values is around the 
mean value. The degree of variation about the measurement for the group is called the 
inter-subject coefficient of variation (CoV). In this study the mean inter-subject CoV for 
FEV1/FVC was 17.2% and for FEV1/FEV6 was 12.7%. 
 
7.3.3 DISCUSSION 
This reduced variability in the FEV1/FEV6 ratio is likely attributed to the FEV6 end-of 
test-point. An explicitly defined end-of-test of six seconds duration tends to increase the 
accuracy of the expired volume measurement. Therefore, with the FEV6 manoeuvre 
terminating the expired volume at exactly six seconds duration variability surrounding 
the end of test volume is reduced. Guidelines on spirometry interpretation27,28 
recommend that only reference equations that are technically and biologically 
appropriate for the population being studied are to be used, as any difference occurring 
between the methods in which the reference value and the actual measured value were 
obtained can lead to errors in interpretation. Therefore given that the shorter FEV6 
manoeuvre has the potential to produce more accurate spirometry results as seen in the 
reduced CoV (table 7.6), interpretation of spirometry results from this type of 
manoeuvre should only be carried out with the appropriate FEV6 reference equations. 
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STUDY B1 
7.4 THE EFFECTS OF AGE ON THE FEV1/FEV6  AND  FEV1/FVC RATIOS 
 
7.4.1 AIM OF STUDY 
In Table 7.5 the patients included in our main study of the comparison of FEV1/FEV6 to 
FEV1/FVC in diagnosing airways obstruction had an age range from 42  to 70 years and  
we therefore choose to look at the effects that age has on the FEV1/FVC and 
FEV1/FEV6 ratios.  
7.4.2 RESULTS 
The mean measured FEV1/FEV6 and FEV1/FVC values by age categories are given in 
table 7.7 
 
TABLE 7.7  MEAN FEV1/FVC AND FEV1/FEV6 BY AGE CATEGORIES 
 
 
 
 
 
 
 
 
 
  
 
 
 
Age years 
(± SD) 
 
N 
 
FEV1/FVC 
(± SD) 
FEV1/FEV6 
(± SD) ∆ (ml) 
FET  
(± SD) 
 
p- value 
 
 
20-29 (± 3.7) 
 
 
4 
 
78.2   
(± 11.1) 
 
78.5  
(± 11.4) 
 
0.25 
 
7.0 
(±0.5) 
 
0.979 
 
30-49 (± 5.7) 
 
 
24 
 
76.5 
 (± 9.0) 
 
78.2  
( ±7.4) 
 
1.6 
 
8.7 
(±2.8) 
 
0.500 
 
50-69 (± 5.0) 
 
 
49 
 
71.1 
 (± 11.5) 
 
75.0 
 (± 8.4) 
 
3.9 
 
10.0 
(±2.8) 
 
0.184 
 
70-89 (± 3.8) 
 
 
22 
 
64.4 
 (± 14.8) 
 
68.4  
(± 11.5) 
 
3.9 
 
9.8 
(±3.0) 
 
0.341 
 
∆ = absolute difference between both ratios expressed in ml 
 
Values for FEV1/FVC and FEV1/FEV6 reported are mean measured values. 
 
 Values for FET are mean average values reported in seconds. 
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Both ratios show a decline with increasing age and increasing forced expiratory time 
(FET). The mean difference between the FEV1/FVC and FEV1/FEV6 ratios was found 
to increase with age from a difference of only 0.25 ml in the younger age bracket 20-29 
years to a mean difference of 3.9 ml in subjects aged > 50years. We found no 
statistically significant difference between both ratios, p<0.05. 
When the data are expressed in graphical form, it is easier to see the decline in both 
ratios with increasing age.The mean FEV1/FVC and FEV1/FEV6 ratios are plotted for 
each age category in Figure 7.1. 
Mean FEV1/FVC and FEV1/FEV6 measured by age 
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FIGURE 7.1   MEAN MEASURED FEV1/FVC AND MEAN MEASURED FEV1/FEV6  IS 
PLOTTED FOR EACH AGE CATEGORY 
 
7.4.3  DISCUSSION  
Maximum lung function is reached at approximately 20 years of age in females and 25 
years of age in males29. This is due to the fact that girls reach puberty and attain their 
maximum lung size earlier than boys of similar age. In males after puberty, although 
growth in stature may cease, growth in lung capacity continues for some years due to 
the continued growth of the thorax29. Lung function has been shown in numerous cross 
sectional and longitudinal studies to decline naturally with age30,31, and therefore the 
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decline in both ratios seen in this study with increasing age is not unexpected. The 
normal annual decline in healthy never-smoking adults 35-65 years old has been 
determined to be on average 30 ml/year 32. In elderly subjects this age related decline is 
accelerated33,34 and can be seen very readily in studies which are conducted for the 
purpose of creating reference equations. Such studies incorporate large numbers of 
healthy individuals of both sexes and represent a wide spectrum of ages.  
A recent study establishing predicted reference values for elderly subjects35 
reported that the annual decline in FEV1 values for healthy elderly females was 32 
ml/year and for healthy elderly males of 44 ml/year. The same study also predicted the 
FEV1/FVC ratio to decline with increasing age from a value of 80% to 70% predicted in 
females and from 79% to 73% predicted in males to the lower limits of normal from 
71% to 68% and from 70% to 64% respectively. In another large reference based study 
conducted in the United States called the National Health and Nutrition Survey III36, 
analysis of some 74,294 healthy subjects revealed a slower decline with age with 
FEV1/FEV6 than with FEV1/FVC. 
Our results mirror these findings showing a less steep decline in FEV1/FEV6 at all ages 
compared to FEV1/FVC, (Figure 7.1). Our results also show that the FEV1/FVC ratio 
declines with the duration of expiratory effort as indicated in the forced expiratory time 
(FET).  This finding reflects how the FVC measurement depends on the time taken to 
empty the lungs forcefully. Longer expiratory times were needed to obtain the FVC 
measurement in subjects over fifty years of age. The age related decline in lung function 
can be accounted for by factors associated with ageing such as loss of elastic recoil of 
the lung that occurs naturally with age. Studies of the effects of ageing on the human 
lung have found that with healthy individuals the elastic recoil pressure decreases as age 
increases37,38. Ageing also brings about changes in the respiratory system and each 
change plays a part in the natural decline of the lung function parameters FEV1 and FVC 
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and hence the ratio FEV1/FVC. These changes include the chest wall becoming stiffer 
with age.This stiffness is termed reduced compliance, and may be linked to calcification 
in the rib bones and the general geometric changes that occur to the rib cage and thorax 
with increasing age.  
Structural changes also affect the force generating capacity of the diaphragm, the 
main muscle used in respiration and coupled with deficient nutritional status that comes 
with age,serve to reduce overall respiratory muscle strength and hence the ability to 
generate expiratory force. The principal cause of age-related decline in lung function is 
attributed to the nature of the tissues that make up the lung and airways called elastic 
and collagen fibers in the lung parenchyma. It is the inherent elasticity of the lungs that 
allows expansion on inspiration and enables them to spring back into shape on 
expiration. The force used here is called the elastic recoil pressure, and ageing causes 
this recoil to diminish, brought on by degeneration or changes in the arrangement of the 
elastic fibers.  
During forced expiration in elderly subjects the chest wall is stiffer and the lungs are 
less elastic allowing inspired air to become trapped within the lungs. This causes the 
residual volume (RV) of the lung to increase and in doing so compromises the overall 
vital capacity and increases the functional residual capacity (FRC). When air is forced 
from the lungs of an elderly subject the natural degeneration of the fibers that support 
the walls of the airway cause the small airway (< 2mm) collapse or close more 
prematurely than they would in younger lungs. This closure or airway narrowing 
prolongs the expiratory time (FET) required to reach the FVC and in turn increases the 
variability of the FVC measurement. This is reflected in the results shown in table 7.6, 
the FVC parameters with larger standard deviations than the FEV6 parameters, and the 
variability in the measurement as reflected by the larger SD increases with increasing 
age. 
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7.4.4 SUMMARY 
This study showed that both FEV1/FVC and FEV1/FEV6 decrease with age, and the 
difference between ratios is more pronounced the older the individual. The results of 
this study also demonstrate the longer the forced expiratory time the greater the 
difference between ratios. We looked at the effects of airway patency on both ratios in 
section B2. 
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STUDY B2 
 
7.5 THE EFFECTS OF THE DEGREE OF AIRWAY PATENCY ON THE 
FEV1/FEV6 AND FEV1/FVC RATIOS 
 
7.5.1 AIM OF STUDY 
The FEV1/FVC ratio is widely used in clinical practice to determine if an obstructive 
ventilatory effect is present and is a measure of the degree of airway narrowing that 
occurs during a forced expiratory manoeuvre39. Using the spirometric data from patients 
included in our main study of the comparison of FEV1/FEV6 to FEV1/FVC in the 
spirometric diagnosis of airways obstruction, we investigated the difference between 
both ratios as the patency of the airway decreases.  
 
7.5.2 RESULTS 
In table 7.8 the absolute difference between the FEV1/FVC and FEV1/FEV6 ratio and 
the corresponding forced expiratory time in four distinct categories based on the degree 
of airway patency as defined by FEV1/FVC are shown. 
The mean difference between the measured FEV1/FVC and FEV1/FEV6 becomes 
greater the more narrow the airways become, as reflected by a decreasing FEV1/FVC 
ratio from a difference of only 0.6 in subjects with an FEV1/FVC of greater than 80 to a 
difference of 11.2 in subjects with an average FEV1/FVC of less than 50. There is also a 
concomitant increase in the forced expiratory time from 7.2 (0.96) seconds to 15.2 
(0.93) seconds. When these data are expressed in graphical form the decline in both 
ratios with decreasing airway patency is very apparent. The mean FEV1/FVC and 
FEV1/FEV6 ratios are plotted for each value of FEV1/FVC in Figure 7.2 
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TABLE 7.8 FEV1/FVC, FEV1/FEV6 AND MEAN FET BY DEGREE OF 
AIRWAY PATENCY AS DEFINED BY THE FEV1/FVC RATIO 
 
 
 
FIGURE 7.2  MEASURED FEV1/FVC AND FEV1/FEV6 BYTHE DEREE OF AIRWAY 
PATENCY AS DEFINED BY THE FEV1/FVC RATIO 
 
 
 
Airway 
patency 
 
FEV1/FVC
(± SD) 
FEV1/FEV6 
(± SD) Difference 
FET 
(± SD)  
 
p-value 
>80 
 (n =24) 
 
83.8 (±2.9) 84.4 (±2.6) 0.6 7.2 (±1.0)  
0.4450 
70-80 
(n = 44) 
 
75.5 (±2.9) 77.6 (±2.7) 2.1 8.7 (±2.0)  
0.0005***
50-69 
(n = 23) 
 
63 (±5.0) 67 (±3.6) 4.0 10.6(±2.6) 
 
 
0.0005***
< 50 
(n =8) 
 
39 (±4.5) 50.2 (±3.2) 11.2 15.2(1±.0.9)  
0.0001***
FEV1/FVC and FEV1/FEV6 above are represented as mean measured values.  
 
Values for FET are mean average values reported in seconds. 
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7.5.3 DISCUSSION 
The FEV1/FVC represents the proportion of air that can be exhaled from the lungs in the 
first second of a forced expiratory manoeuvre in relation to the maximum volume of air 
that can be expelled from the lungs. The amount expired in the first second is a constant 
fraction of that which can be maximally exhaled. The difference between FEV1/FVC 
and FEV1/FEV6 becomes more pronounced the more reduced the FEV1/FVC becomes, 
from a difference of 0.6 in the group with an FEV1/FVC ratio of > 80, to a difference of 
11.2 in the group with an FEV1/FVC ratio of <50, there is also a concomitant increase 
in the time taken to empty the lungs forcefully (FET), 7.2 seconds to 15.2 seconds 
respectively.  
These results clearly show that the more reduced the patency of the airways the longer 
the FET becomes and this can be attributable to a number of factors. With a reduced 
airway patency known as airflow obstruction the diameter of the airways affected is 
narrowed due to excess mucous production and inflammation of the surrounding airway 
wall. This narrowing may also be due to a reduced elastic recoil pressure as discussed 
earlier which can cause the small airways to narrow early in the forced expiration, 
leading to a longer forced expiratory time. The significant difference observed in our 
limited study between ratios in the case of decreasing airway patency has the potential 
of causing misclassification when it comes to interpreting spirometry results.  
In some subjects with airways obstruction the time taken to reach the ‘end-of-test 
criterion’ is prolonged well beyond six seconds and  the more pronounced the difference 
between the FEV6 end of test and the FVC end-of-test point will be.  
 Figure 7.3 shows a sample volume time curve to illustrate the difference between a 
FVC manoeuvre and a FEV6 manoeuvre. 
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FIGURE 7.3  SPIROGRAM DEPICTING THE DIFFERENCE BETWEEN THE TWO END OF 
TEST POINTS FVC AND FEV6 
 
 
 In this example the time taken to forcefully exhale a vital capacity breath is 
approximately 14 seconds, giving an FVC in this example of 4.9 litres. If the curve is 
truncated at six seconds (vertical line at 6 seconds) as would be the case in the shorter 
six second manoeuvre, the resulting forced expiratory volume at six seconds (FEV6 ) is 
4.6 litres. The forced expiratory volume after one second of exhalation (FEV1) is 3.3 
litres and this is the same regardless of the type of manoeuvre used. The FEV1/FVC 
ratio is calculated to be 67 but the FEV1/FEV6 ratio due to the smaller denominator is 
greater at 72, therefore the shorter FEV6 manoeuvre could underestimate the degree of 
airway patency and so create a false negative interpretation. However the potential for 
misclassification should be minimised if the correct reference values that have been 
derived from the same type of manoeuvre are used.  
Interpretation of spirometry employs reference equations that are appropriate both to the 
measurement and to the population being studied. Clinical practice guidelines for 
spirometry interpretation endorse the use of the appropriate reference equations and 
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lower limits of normal to accurately define airflow obstruction40. If the appropriate 
reference equations with well described lower limits of normal are used the difference 
between a manoeuvre lasting six seconds and the longer FVC manoeuvre will be 
accounted for. This was investigated by Demir et al41, who found in a study of 5,114 
subjects that among those with an FEV1/FVC ratio of less than 70, only 86% also had 
an FEV1/FEV6 less than 70, and that the mean difference between FEV1/FVC and 
FEV1/FEV6 expressed as percentages increased from approximately 4 to 9 when 
FEV1/FVC decreases from 70% to 50%. They found that if this difference is taken into 
account using appropriate reference equations for FEV1/FEV6, then the FEV1/FEV6 
ratio from the shorter FEV6 manoeuvre is as good a predictor of airways obstruction as 
the traditional longer FEV1/FVC.   
 
7.5.4 SUMMARY 
We found in this study that a reduced airway patency causes a prolonged average FET. 
The longer the FET the greater the difference between the ratios FEV1/FVC and 
FEV1/FEV6. However as other studies have pointed out, using the correct reference 
equations and lower limits of normal, FEV1/FEV6 may be used as a surrogate for 
FEV1/FVC despite having a fixed shorter FET. This was investigated in our study 
population and the results are presented in Section C of this chapter. 
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SECTION B3 
 
7.6 FEV1/FEV6 COMPARED TO FEV1/FVC IN THE SPIROMETRIC 
DETECTION OF AIRWAYS OBSTRUCTION  
 
7.6.1 AIM OF STUDY 
The importance of a diagnostic test is its ability to give the correct diagnosis. It is 
unlikely that any diagnostic test is ever accurate all of the time. The diagnostic test of 
the FEV1/FEV6 ratio, to be useful must be sensitive enough to determine the correct 
diagnosis of airways obstruction in the substantial majority of cases. In this study the 
diagnostic ability of FEV1/FEV6 in identifying airways obstruction was tested by 
comparison with the ‘gold standard’ FEV1/FVC ratio. Patients were classified into two 
distinct groups according to the presence or absence of airways obstruction as defined 
by a FEV1/FVC and a FEV1/FEV6 above or below their respective lower limit of normal 
values. Results are presented in table 7.9. 
 
 7.6.2 RESULTS 
Twenty six out of the ninety nine subjects included in this study had a diagnosis of 
airways obstruction confirmed by both FEV1/FVC and FEV1/FEV6 and seventy one 
subjects had a diagnosis of no airways obstruction confirmed by both ratios. There were 
two cases where the diagnosis of airways obstruction differed between ratios, these 
were called discordant cases. One subject was diagnosed as having airways obstruction 
by the FEV1/FVC ratio alone and the other was diagnosed as having airways obstruction 
by the FEV1/FEV6 ratio alone. Sensitivity for the group was calculated to be 96%, 
specificity 98%, positive predictive value 95% and a negative predictive value of 98%. 
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TABLE 7.9  DIAGNOSIS OF AIRWAYS OBSTRUCTION USING PRECISE 
LOWER LIMITS OF NORMAL FOR FEV1/FVC AND FEV1/FEV6 
 
 
7.6.3 DISCUSSION 
The proportion of patients with airways obstruction who were correctly diagnosed by 
the FEV1/FEV6 ratio (sensitivity) is 96.3% and those with no airways obstruction who 
were correctly identified by the FEV1/FEV6 ratio (specificity) is 98.6%. Therefore, in 
these patients we would expect 96.3% of patients with airways obstruction to be 
correctly identified by the FEV1/FEV6 ratio while 98.6% would be correctly identified 
as not having airways obstruction by the same ratio. If a patient is confirmed as having 
airways obstruction by the gold standard FEV1/FVC ratio there is a 96.3% probability 
that the same patient would also be confirmed as having airways obstruction using the 
FEV6 manoeuvre. In this study the use of the FEV6 manoeuvre in predicting 
abnormality was also calculated and given as positive predictive value (PPV) and 
negative predictive value (NPV) in table 7.4. A PPV of 95.6% represents the proportion 
  FEV1/FVC 
                                 Obstruction                 No Obstruction                   Total 
FEV1/FEV6 
Obstruction 
 
26 
 
1 
 
27 
FEV1/ FEV6 
No Obstruction 
 
1 
 
 
71 
 
72 
Total 27 72 99 
 
Sensitivity: 96.3%, Specificity: 98.6%, Positive predictive value (PPV): 95.6% 
Negative predictive value (NPV): 98.8% 
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of patients with airways obstruction for which the FEV6 manoeuvre correctly identified 
them as having airways obstruction. A NPV of 98.8% shows the proportion of patients 
without airways obstruction which the FEV6 manoeuvre correctly identified. The 
calculation of these predictive values is highly dependant on the prior probability of 
disease in the population being studied. This is known as disease prevalence. The 
prevalence of obstruction in this study population was calculated to be 24/99 (24%). 
This meant that before applying the above diagnostic accuracy test; there was a prior 
probability (24% chance) that a given patient would have airways obstruction.  
These results confirm that replacement of the FVC ‘gold standard’ manoeuvre with a 
shorter FEV6 manoeuvre and the use of proper reference equations in our patient 
population would not diminish the diagnostic accuracy of the spirometry test in 
identifying airways obstruction. The sensitivity of the FEV6 method of 0.96 means that 
if a patient is confirmed as having airways obstruction by the gold standard FVC 
method there is a 96% chance that that same patient will also be diagnosed as having 
airways obstruction by the FEV6 method. Consequently, this leaves 4% of the subjects 
studied who may be classified as not having airways obstruction, despite having the 
disorder. The specificity result of 0.98 on the other hand provides the scenario that a 
subject may be identified as not having airways obstruction by the FVC method there is 
a 2% chance that the same subject may be identified as having airways obstruction by 
the FEV6 method.  An example of this method in practice is shown in table 7.9 for two 
cases reported where the two ratios under investigation produced two differing diagnose 
or discordant cases. 
 
DISCORDANT CASES 
The spirometry test results for two patients were classified differently by the two ratios; 
however both had observed values close to their respective lower limits of normal. 
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Subject characteristics and spirometry data are presented in Table 7.10. In the first 
discordant case the FEV1/FVC was above its corresponding lower limit of normal and 
therefore no airways obstruction was deemed to be present. FEV1/FEV6 was at its lower 
of limit of normal value and in clinical practice this subject would be deemed to have 
airways obstruction. In the second discordant case the FEV1/FVC ratio classified an 
obstructive ventilatory pattern as the measured value was at the lower limit of normal 
but the FEV1/FEV6 was above its lower limit of normal and therefore airways 
obstruction was deemed to be absent in this subject by this ratio. 
 
TABLE 7.10  DISCORDANT CASES 
 
 
 
 
 
 
 
Both discordant cases have ratios that lie close to their lower limits of normal and 
therefore should be interpreted with caution. The day-to-day variation that occurs in 
spirometric measurements could shift the results across the lower limit of normal value. 
 Lung function has been shown to exhibit both diurnal and seasonal variation due to 
factors such as cyclical changes in blood cortisol and adrenaline levels, ambient 
temperature, airways resistance sleep patterns, posture, meals and hormone production 
in females42. Reported significant changes in FVC and FEV1 for normal subjects within 
a day are 5%, this variability has been shown to increase to 13% for patients with 
chronic obstructive pulmonary disease. The equivalent weekly variation in these two 
Subject Age 
(years) 
FET 
(seconds) 
Gender FEV1/FVC
(LLN) 
FEV1/FEV6 
(LLN) 
1 62 6.5 Female 69 (64) 69 (69) 
 
2 63 12.2 Male 65 (65) 72 (70) 
 
LLN refers to lower limit of normal 
Difference refers to the measured value minus the lower limit of 
normal. 
Age is in years 
Forced expiratory time (FET) is in seconds 
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spirometry parameters is 11% and 20% respectively43,44. In the context of the results 
seen in this study and in particular in the two discordant cases shown in table 7.6, 
results that lie close to their lower limit of normal can easily shift across this lower limit 
of normal threshold and be subject to a different diagnosis. Joint American Thoracic 
and European Respiratory Society guidelines on lung function interpretation 
recommend caution when interpreting spirometry results that lie close to the lower limit 
of the reference range and recommend clinical history and prior probability of disease 
as adjuncts in making a definitive diagnosis in these circumstances.The results of this 
study are similar to two other large studies published on this same topic. Compared to 
Swanney et al.45 in our study we obtained slightly higher values of sensitivity and 
specificity (96%, 98% in our study compared with 95% and 97%). Swanney et al had a 
larger population of patients (n = 337) with a prevalence of obstruction of 65.5%. 
Similarly we obtained higher values in comparison with the Vandervoode et al study46 
which had a patient population of 11,676 and a prevalence of obstruction of 39.5%. 
 
7.6.4  SUMMARY  
As discussed in Chapter 6 the reference values used in this study are the only published 
references equations to date that include the FEV6 parameter in the age range 8-
80(years). Using the reference equations and lower limits of normal taken from a large 
American Health Study NHANES III this study demonstrated that the FEV6 manoeuvre 
can be used as a surrogate for the FVC manoeuvre in the identification of airways 
obstruction in our patient population. We also found a much reduced inter-subject 
coefficient of variation in the FEV6 parameter, suggesting that stopping the test at a pre-
defined time of six seconds can significantly reduce the variability of the measurement 
and make it a more reproducible and accurate physiological measurement, while not 
losing its diagnostic ability. 
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SECTION C 
7.7 FEV1/FEV6 AS A SUBSTITUTE FOR FEV1/FVC IN A SUBGROUP OF 
ELDERLY PATIENTS USING TWO SETS OF REFERENCE 
EQUATIONS  
 
7.7.1 AIM OF STUDY 
This study was conducted to determine the reliability of FEV6 and FEV1/FEV6 in 
detecting airways obstruction in an elderly patient group aged 65-85 years using 
European reference values specific to this age group (García-Río et al.)47 and to evaluate 
the sensitivity and reliability in detecting airways obstruction using both the American 
(NHANES III)48 and the European (García-Río et al.) reference values in this elderly 
population. It is in this group of patients that the shorter FEV6 spirometry test may be of 
most benefit. As documented in Study B Section 7.3, the forced expiratory time 
generally becomes longer with age and so a shorter test will minimize the burden 
involved in reaching the standard end -of -test point.  
The European reference equations used in this study are the first and only published 
spirometric equations to date extracted from a European population of elderly patients 
to include the new FEV6 parameters.  
 
7.7.2 RESULTS 
In this study we had a total of n= 68 patients, n=35 female and n=33 male. Mean age of 
the group was 72 (5.2) years, mean height 167(9.8) centimeters, with females on 
average 14 cm shorter than males (Table 7.11). The mean forced expiratory time for the 
group was 9.6 (2.6) seconds. The mean measured spirometry parameters are shown in 
table 7.12. Mean measured FEV1/FVC for the group is 68.3 with a SD of 12.2 compared 
to FEV1/FEV6 of 72.2 with a smaller SD of 9.8. 
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TABLE 7.11  SUBJECT DEMOGRAPHICS 
 Male n = 33 Female n = 35 Total n = 68 
Mean Age (years) 72.2   4.8 72.5   5.7 72.4 5.2 
Mean Height (cm) 174    6.4 160  7.4 167 9.8 
Mean FET (sec) 9.8   2.5 9.4  2.8 9.6 2.6 
 
TABLE 7.12  SPIROMETRY DATA 
Spirometry Parameter Mean (± SD) 
FVC measured 2.6 ±  0.8  
FEV6 measured 2.5 ± 0.8 
FEV1 measured 1.8 ± 0.7 
FEV1/FVC measured 68.3 ± 12.2 
FEV1/FEV6 measured 72.0 ±  9.8 
FET 9.6 ± 2.6 
 
The comparison of FEV1/FVC and FEV1/FEV6 with reference equations and lower 
limits of normal from the NHANES III reference set is expressed in a 2-by-2 
contingency table (table 7.13). The ratios matched for diagnosis in all but one case 
where FEV1/FEV6 diagnosed airways obstruction and the FEV1/FVC categorized this 
subject to have no airways obstruction (table 7.14). The sensitivity of the FEV1/FEV6 
ratio for correctly diagnosing airways obstruction in this elderly cohort was calculated 
to be 100%, specificity 98%, with a positive predictive value of 95% and a negative 
predictive value of 100%.  
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TABLE 7.13  CONTINGENCY TABLE USING NORTH AMERICAN  
(NHANES III) REFERENCE EQUATIONS 
 
 
TABLE 7.14   DISCORDANT CASE USING NHANES III REFERENCE 
VALUES 
 
 
 
 
 
 
 
 
This calculation was repeated using reference equations and lower limits of normal from 
the Garcia-Rio reference set, results are expressed as a 2-by2 table (Table 7.15). Using 
these equations the sensitivity of FEV1/FEV6 was calculated to be 96%, with specificity 
95% ,and positive predictive value of 92.6%, and a negative predictive value of 97.5%. 
FEV1/FVC 
 Obstruction No Obstruction Total 
FEV1/FEV6 
Obstruction 
21 1 22 
FEV1/FEV6 
No Obstruction 
0 46 46 
Total 21 47 68 
Sensitivity: 100% Specificity: 98%  Positive predictive value (PPV): 95% Negative predictive value 
(NPV): 100%  
Subject Age 
(years) 
FET 
(secs) 
Gender FEV1/FVC 
(LLN) 
FEV1/FEV6 
(LLN) 
1 78 6.5 Female 69 (64) 69 (69) 
LLN refers to lower limit of normal 
Difference refers to the measured value minus the lower limit of normal. 
Age is displayed in years 
Forced expiratory time (FET) is displayed in seconds 
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FEV1/FVC and FEV1/FEV6 disagreed in their diagnoses of airways obstruction in three 
cases using this reference set (Table7.16).  
TABLE 7.15 CONTINGENCY TABLE USING EUROPEAN (GARCIA-RIO) 
REFERENCE EQUATIONS 
 
FEV1/FVC 
 Obstruction No obstruction Total 
FEV1/FEV6 
Obstruction 
25 2 27 
FEV1/FEV6 
No obstruction 
1 40 41 
Total 26 42 68 
Sensitivity:96% Specificity: 95% Positive predictive value (PPV): 92.6
 Negative predictive value (NPV): 97.5  
 
TABLE 7.16   DISCORDANT CASES USING GARCIA-RIO REFERENCE 
VALUES 
 
 
 
 
 
 
 
 
 
 
Subject Age 
(years) 
FET 
(secs) 
Gender FEV1/FVC 
(LLN) 
FEV1/FEV6 
(LLN) 
1 70 10.1 Female 62 (68) 70 (69) 
2 67 7 Male 71 (70) 71 (72) 
3 77 12.2 Male 65(67) 72 (69) 
LLN refers to lower limit of normal 
Difference refers to the measured value minus the lower limit of normal. 
Age in years 
Forced expiratory time (FET in seconds) 
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7.7.3 DISCUSSION  
The main aim of this study was to investigate the diagnostic ability of the shorter six 
second manoeuvre in a subgroup of patients that have longer forced 
expiratory times (FET), due to the natural ageing process of the lung and loss of 
elastic recoil49. Elderly patients may benefit most from a shorter spirometry manoeuvre, 
as less effort is required to reach the end of test point.  From our results in Section 7.1, 
we found that the mean difference between the FEV1/FVC and FEV1/FEV6 ratios 
increased with increasing age and forced expiratory time but using reference equations 
with LLNs that included FEV6 parameters, we calculated the diagnostic ability of the 
FEV1/FEV6 to correctly diagnose airways obstruction was 96.3%. 
The FEV1/FVC ratio obtained from a spirometry or forced vital capacity manoeuvre is 
widely used in clinical practice to determine the presence of an obstructive ventilatory 
defect or airways obstruction50,51,52. An obstructive ventilatory defect is defined as a 
disproportionate reduction of maximal airflow from the lungs in relation to the maximal 
volume that can be displaced from the lung53. As the FEV1/FVC ratio is based on the 
maximal volume of air that can be exhaled during a spirometry test the accuracy of this 
ratio becomes entirely dependent on patient effort and co-operation. In spirometry 
testing the ability to reach an acceptable exhaled volume or end of test point and the 
ability to reproduce this volume to within 150 ml as stated in the most recent guidelines 
on the standardization of spirometry testing53 can be especially difficult for elderly 
patients and patients with severe airways obstruction. These patients often require up to 
20 seconds  to reach what is accepted as an adequate end-of-test point of a volume 
change of <25 ml over 2 seconds.  
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An alternative end-of test-point, where the forced expiratory volume is explicitly 
confined to 6 seconds duration has been suggested to be a more accurate less variable 
measurement and one that may be less demanding to perform. 
There are numerous reference equations published for forced spirometry 
parameters such as the FVC and the FEV1; in the Republic of Ireland over 90% of 
pulmonary function laboratories have adopted the 1993 Update European Respiratory 
Society spirometry reference values for adults aged 18-70 years54 for their patient 
population. Two published reference equations exist for the FEV6 parameter and its 
ratio FEV1/FEV6. The Third National Health and Nutrition Examination Survey 
(NHANES III) which was derived from a US population aged 8-80 years and the 
reference equations by García-Río et al. derived from a Spanish population with an age 
range of 65-85years. Studies to date using the NHANES III US reference values for 
FEV6 and FEV1/FEV6 have shown FEV6 to be reliable alternative for detecting airways 
obstruction (and restriction) in spirometry testing55,56 and that FEV6 can be used as a 
surrogate for FVC in the workplace setting57.  
Another study published fixed cut-off-points for FEV6 and FEV1/FEV6 that can 
be used as a valid alternative to the FVC and FEV1/FVC ratio in the detection of 
airways obstruction58. European reference values and lower limits of normal published 
to date that include values for FEV6, FEV1/FEV6 and apply to subjects in the age range 
of 65-85 years. However it is in this particular group of patients that a shorter test 
manoeuvre may be of greater benefit, as it may prevent the undue fatigue and 
discomfort and in some cases syncope that can be associated with the standard 
prolonged test manoeuvre. In our study we documented that the average forced 
expiratory time for the group as a whole was 9.8 seconds, well above the suggested six 
second cut off point. The longer forced expiratory times (FET) in this particular cohort 
of patients may be due in part to the natural ageing process of the lung. The loss of 
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elastic recoil in ageing lungs can mimic an airways obstructive pattern59. The difficulty 
with longer forced expiratory times is that they push the standard criteria for end-of-test 
further along the expiratory time curve, making it increasingly difficult for the patient to 
reach them. The shorter FEV6 manoeuvre has a definite end-of-test of six seconds 
duration and so can reduce the effort required by the patient and by the test operator to 
meet a longer FVC end of test point. It can reduce overall testing time and may actually 
assist in interpretation by reducing the variability of the volume measurement, making it 
statistically more accurate when compared with reference values for the same 
measurement. In the present study using contingency tables and lower limits of normal, 
tables 7.13 and 7.14, we have shown significant agreement between FEV1/FEV6 and 
FEV1/FVC in terms of diagnosing airways obstruction in both sets of reference 
equations for our elderly cohort and these findings reflect the values obtained in 
previous studies in other countries. However we did not get 100% agreement and where 
the ratios differed in diagnosis (discordant cases) the actual measured values for each 
ratio is very close to its respective lower limit of normal. This was the first study to date 
to look at the new FEV6 parameters in terms of diagnosing airways obstruction in a 
strictly elderly group of patients, and the first to compare the differences between the 
two main reference equations published to date to include FEV6 equations and lower 
limits of normal. 
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7.7.4  SUMMARY 
The results of this study confirm that FEV6 is a more reproducible parameter by 
showing the coefficient of variation for FEV1/FEV6 to be 23% less than that for 
FEV1/FVC. This reduced variability suggests that the FEV1/FEV6 may be a more 
statistically accurate ratio for detecting airways obstruction. 
Recently published joint ERS/ATS guidelines on the standardization of spirometry 
define an acceptable duration of exhalation as ≥ 6 seconds or the presence of a plateau 
to define end-of-test criteria, making way for this new FEV6 parameter to be recognised 
as an acceptable surrogate for FVC provided the correct reference values are used. This 
work suggests there is need for updated European reference equations to be made 
available to include FEV6 and FEV1/FEV6 for all age groups. This study has shown 
reduced variability of FEV1/FEV6 compared to FEV1/FVC and therefore that FEV6 has 
a role in spirometry testing, especially for patients unable to reach a satisfactory FVC 
endpoint. The agreement of FEV1/FVC and FEV1/FEV6 using both reference sets and 
the sensitivity/specificity of FEV1/FEV6 in this cohort support the validity of using 
FEV6 in the diagnosis of airway obstruction.  
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CHAPTER 8  CONCLUSIONS 
The utility of a shorter six second manoeuvre in spirometry testing has been assessed in 
this thesis with a special emphasis showing that spirometric indices measured at six 
seconds are clinically useful in detecting airways obstruction. The clinical utility of the 
traditional FVC manoeuvre has already been well established with the FEV1/FVC ratio 
now firmly accepted as an indicator of the presence of airflow obstruction. However the 
FVC manoeuvre is not without problems. The prolonged forced expiratory times 
required to meet acceptable end-of-test criteria can be physically exhausting for subjects 
with airways obstruction and for elderly and infirm subjects. Also measurements with 
expiratory times that take up to or exceed 15 seconds have the potential to cause an 
increase in measurement variability. In addition an increase in the prevalence of 
respiratory disease worldwide, particularly COPD, has led to a renewed interest in 
making spirometry testing more user-friendly and less variable, thereby facilitating 
widespread implementation of spirometry as a means of detecting airways obstruction 
in its sub-clinical phase.  
An alternative to the traditional FVC manoeuvre is the forced vital capacity at six 
seconds (FEV6). In our investigations into the clinical utility of the FEV6 manoeuvre we 
investigated if parameters measured at six seconds exhalation could provide any 
additional information regarding early detection of airways obstruction in smokers with 
otherwise normal spirometry values. The findings of this study revealed that a 
significant difference existed in the FEV1/FVC ratio between smokers and non-smokers 
and that the FEV1/FEV6 ratio mirrored this finding. While the FEV6 parameters did not 
provide us with any additional information regarding early indicators of airways 
obstruction, parameters measured at six seconds can be successfully used as a surrogate 
for the FVC manoeuvre in this study group. We also found that parameters measured at 
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six seconds are less variable and therefore are more easily interpreted with accuracy. 
The findings of this section of the thesis reveal that the FEV6 measurement has a role to 
play in spirometry testing but further studies regarding its diagnostic ability are 
required. A longitudinal study of the spirometry results of smokers compared to non-
smokers to include parameters measured at six seconds would give further scope to 
properly assess the merits of the FEV1/FEV6 ratio in providing additional information 
regarding accelerated lung function decline in smokers.  
The diagnostic ability of the FEV1/FEV6 ratio to reliably detect airways obstruction 
using appropriate reference equations and lower limits of normal compared to the ‘gold 
standard’ FEV1/FVC ratio was assessed. The results of this thesis confirm that forced 
expiratory volume in six seconds FEV6 can be used as a surrogate for FVC in our adult 
patient population. We also confirmed that FEV6 spirometry values are more 
reproducible and less variable than FVC values. We also compared FEV6 to FVC in 
terms of detecting airways obstruction in an elderly patient group aged 65-85 years 
using two different reference sets. One set was from a North American population, and 
the second set was the only European spirometry reference set to date to include FEV6 
parameters, and specific to the age group being studied, 65-85 years. It is for this 
specific age group that a shorter spirometry manoeuvre such as the FEV6 would be of 
greater benefit by easing the burden of the test. Given the naturally longer forced 
expiratory times that accompany natural ageing of the lung the potential for larger 
differences between parameters measured at the traditional FVC manoeuvre and those 
measured at six seconds exhalation FEV6 exist.  The findings of this study confirm that 
the FEV1/FEV6 is as good as FEV1/FVC in detecting airways obstruction in this age 
group using both reference sets in our patient population. Where diagnosis differed 
between ratios, the actual measurements when inspected lay close to their respective 
lower limit of normal values. A spirometry value close to, or at, its lower limit of 
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normal value could be due to the day-to-day variation shift across this limit, meaning 
the same test may yield a different diagnosis if repeated some days apart. Therefore 
spirometry values that lie close to their lower limit of normal value should be 
interpreted with caution. 
 
8.1 SUMMARY 
This work demonstrates that the shorter FEV6 manoeuvre is as effective as the 
traditional FVC manoeuvre in the detection of airways obstruction in our patient 
population, provided the appropriate reference equations and lower limits of normal are 
used. We found the FEV6 parameter to be more reproducible than the FVC parameter, 
with prolonged expiratory times having a smaller impact on FEV6 reproducibility than 
on FVC reproducibility.  
The physical impact of a shorter FEV6 manoeuvre will be more pronounced in subjects 
where multiple prolonged forced expiratory efforts are commonly required to satisfy 
reproducibility criteria, for example with elderly subjects and subjects with airways 
obstruction. Lowering the forced expiratory time to six seconds will reduce the 
likelihood of procedure related syncope (which is light headiness, faintness) general 
fatigue and distress that can accompany a session of numerous prolonged forced 
expiratory efforts. A fixed expiratory time of six seconds has been shown in this study 
to significantly reduce the variability of the test, and therefore improve the overall 
accuracy of the test. In addition the agreement of both FEV1/FVC and FEV1/FEV6 in 
terms of sensitivity and specificity support the validity of using FEV6 in the spirometric 
detection of airways obstruction. 
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8.2 Further Work 
Using FEV6 based spirometry values to detect airways obstruction could increase the 
popularity of spirometry testing in the primary care setting where the number quality of 
testing may not be as good as that in a hospital based lung function department. The 
shorter test manoeuvre coupled with the reduced variability of this measurement may 
provide a means of reducing the risk of mis-classification in this setting. As we have 
shown in this work FEV6 parameters are less variable and therefore more reproducible 
than the standard FVC parameters. We have also shown that among other spirometric 
parameters the FEF25-75% is significantly reduced in smokers compared to non-smokers. 
The diagnostic ability of the FEF25-75% has always been limited because of its high 
variability; this was demonstrated in our work with inter-subject SD values of up to 
29.0, compared to SD values for FEV6 of approx 12.0.  
The greater variability in this measurement is partly due to the variability of the FVC 
measurement, since this measurement is calculated from 25% and 75% of the end value 
FVC. Determining FEF25-75% from a six second manoeuvre, which has proven to be less 
variable, may provide a more accurate means of detecting early airway changes 
compared to other tests of lung function.  
For more work to be carried out on the clinical utility of the FEV6 manoeuvre in 
pulmonary function new updated European reference equations and lower limits of 
normal for spirometry values to include FEV6 are required over a wide age range, and 
especially for subjects over the age of 75 years.  
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APPENDIX A 
 
RANGE AND ACCURACY RECOMMENDATIONS FOR SPIROMETERS* 
 
Test Range/accuracy (BTPS) Flow 
Range 
Time 
L.s-1 
Resistance and  
Back pressure 
Test Signal 
VC 0.5-8 L, ±3% of reading or 
± 0.050 l, whichever is 
greater 
0-14 30  3-L Calibration 
syringe 
FVC 0.5-8 L, ±3% of reading or 
± 0.050 l, whichever is 
greater 
0-14 15 <1.5cmH20.L-1.s-1 
(0.15 kPa.L-1.s-1) 
24 ATS waveforms 
3-L Calibration 
syringe 
FEV1 0.5-8 L, ±3% of reading or 
± 0.050 l, whichever is 
greater 
0-14 1 <1.5cmH20.L-1.s-1 
(0.15 kPa.L-1.s-1) 
 
Time zero The time point from which 
all FEVt measurements are 
taken 
  Back Extrapolation   
PEF Accuracy: ± 10% of reading 
or ± 0.30L.s-1 (20 L.min-1) 
whichever is greater; 
repeatability: ±5% of reading 
or ±0.15 L.s-1 
 (10 L.min-1), whichever is 
greater  
0-14  Mean resistance at 
200, 400, 600 L.min-1 
(3.3, 6.7, 10 L.s-1) 
must be <2.5 
cmH20.L-1.s-1 (0.25 
kPa.L-1.s-1) 
26 ATS waveforms 
Instantaneous 
flows  
(except PEF) 
Accuracy ± 5% of reading or 
± 0.200 L.s-1 , whichever is 
greater 
0-14  <1.5cmH20.L-1.s-1 
(0.15 kPa.L-1.s-1) 
Data from 
manufacturers 
FEF 25-75% 7.0 L.s-1, ± 5% of reading or 
± 0.200 L.s-1 , whichever is 
greater 
± 14 15 Same as FEV1 24 ATS waveforms 
MVV 250 L.min-1 at VT of 2 L 
within ± 10% of reading or ± 
15 L.min-1, whichever is 
greater 
± 14 
(±3%) 
12-
15 
<1.5cmH20.L-1.s-1 
(0.15 kPa.L-1.s-1) 
Sine wave pump 
BTPS: body temperature and ambient pressure saturated with water vapour; VC: vital capacity; FVC: forced vital 
capacity; ATS: American Thoracic Society; FEV1: forced expiratory volume in one second; FEVt: forced 
expiratory volume in t seconds; PEF: peak expiratory flow; FEF25-75%: mean forced expiratory flow between 25% 
and 75% of FVC; MVV: maximum voluntary ventilation; VT: tidal volume. 
 
* Millar MR, Hankinson J, Brusasco V, Burgos R ,Casaburi R,Coates A, Crapo R,Enright P et al. 
Standardisation of spirometry. Eur Respir J 2005; 26: 319-338 
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APPENDIX B 
SUMMARY OF WITHIN-AND-BETWEEN-MANOEUVRE ACCEPTABILITY 
CRITERIA* 
 
 
Table 5  Summary of within-and between-manoeuvre  
               acceptability criteria 
 
Within-manoeuvre criteria 
 
Individual spirograms are “acceptable” if 
They are free from artefacts [3] 
     Cough during the first second of exhalation 
     Glottis closure that influences the measurement 
     Early termination or cut-off 
     Effort that is not maximal throughout 
     Leak 
     Obstructed mouthpiece 
They have good starts 
     Extrapolated volume < 5% of FVC or 0.15L, whichever is greater 
They show satisfactory exhalation 
     Duration of ≥ 6 s (3s for children) or a plateau in the volume-time curve or 
     If the subject cannot or should not continue to exhale 
 
Between-manoeuvre criteria 
 
 After three acceptable spirograms have been obtained, apply the following 
      tests 
      The two largest value of FVC must be within 0.150 L of each other 
      The two largest value of FEV1 must be within 0.150 L of each other 
 If both of these criteria are met, the test session many be concluded 
 If both of these criteria are not met, continue testing until 
     Both of the criteria are met with analysis of additional acceptable spirograms
     or 
   A total of eight tests have been performed (optional) or 
   The patient/subject cannot or should not continue 
 Save, as a minimum, the three satisfactory manoeuvres 
 
FVC: forced vital capacity; FEV1: forced vital capacity in one second 
 
 
 
 
* Millar MR, Hankinson J, Brusasco V, Burgos R ,Casaburi R,Coates A, Crapo R,Enright P et al. 
Standardisation of spirometry. Eur Respir J 2005; 26: 319-338 
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APPENDIX C 
 
DEFINITION OF LUNG VOLUMES AND CAPACITIES* 
 
 
 
 
 
 
 
 
 
 
 
 
 
Volume (units: millilitres) Definition 
Tidal volume (Vt) Volume of gas inhaled and exhaled during each 
respiratory cycle 
Inspiratory reserve volume 
(IRV) 
 
Maximal volume of gas exhaled from end 
inspiration 
Expiratory reserve volume 
(ERV) 
 
Maximal volume of gas exhaled from end 
expiration 
Residual volume (RV) 
 
Volume of gas remaining in the lungs after a 
maximal expiration 
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APPENDIX D 
 
 
 
Vmax Series          
 
 
 
 
 
SPECIFICATIONS 
 
 
    Note 
 
   Features and specifications are subject to change  
   without notice. 
 
Flow Volume Measurements 
 
Flow Volume 
 
 
Type 
 
Mass Flow sensor 
 
 
Range 
 
0-16 LPS 
 
 
Resolution 
 
0.003 LPS from 0.20 – 16 LPS 
 
 
Flow accuracy 
 
±3% of reading or 0.25 LPS, whichever is greater, across the range of 0.2 to 
12 LPS 
 
 
Volume 
accuracy 
 
±3% of reading or 0,050 L, whichever is greater 
 
 
 
Resistance 
 
<1.5 cmH20/LPS at 12 LPS 
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APPENDIX E 
 
EXCLUDED GROUP (EXCLUDED ON THE BASIS OF NOT MEETING 
CRITERIA AS SET OUT IN TABLE 6.1) 
 
No Reason for Exclusion Hgt FET Gender FEV1/FVC M FEV1/FEV6M 
1 Early Glottic closure 161 7.31 Female 89 89 
2 Slow start 154 9.34 Female 58 63 
3 Slow start 159 7.07 Male   81 81 
4 Early Glottic closure 157 9.7 Female 75 77 
5 Slow start 163 6.45 Female 72 73 
6 Slow start 187 8.46 Male   78 80 
7 end of test not met 176 8.75 Male   74 76 
8 only 2 acc tests 173 6.44 Male   89 91 
9 end of test not met 176 9.66 Male   66 69 
10 only 2 acc tests 153 7.08 Female 74 74 
11 end of test not met 173 8.46 Male   84 86 
12 end of test not met 156 10.88 Female 69 75 
13 end of test not met 144 6.05 Female 74 76 
14 Slow start 161 9.17 Female 66 69 
15 cough  166 10.14 Male   70 73 
16 end of test not met 170 10.14 Male   47 53 
17 end of test not met 170 14.2 Male   47 55 
18 cough  159 7.4 Female 59 59 
19 end of test not met 165 7.19 Female 85 85 
20 end of test not met 185 13.78 Male   38 48 
21 non-reproducible 184 12.11 Male   67 72 
22 cough  164 7.54 Female 80 80 
23 cough  174 15.98 Male   59 69 
24 Slow start 172 7.06 Male   80 81 
25 glottic closure 165 6.67 Female 82 82 
26 non-reproducible 158 12.22 Female 69 75 
27 glottic closure 174 6.61 Male   87 88 
28 end of test not met 178 6.36 Male   98 98 
29 cough  153 9.17 Female 69 72 
30 end of test not met 188 7.01 Male   96 96 
31 end of test not met 149 6.38 Female 58 58 
32 end of test not met 177 6.73 Male   86 86 
33 Slow start 162 7.57 Female 84 84 
34 cough  158 7.46 Female 78 80 
35 end of test not met 167 9.74 Male   57 61 
36 end of test not met 184 7.74 Male   77 80 
37 end of test not met 177 8.34 Male   50 55 
38 end of test not met 150 11.18 Female 75 80 
39 non-reproducible 166 6.54 Female 87 87 
40 non-reproducible 156 10.75 Female 60 66 
41 Slow start 175 11.18 Male   38 44 
42 Slow start 189 11.23 Male   72 75 
43 non-reproducible 174 6.55 Male   46 46 
44 non-reproducible 177 9.02 Male   80 83 
45 non-reproducible 169 8.33 Male   78 79 
46 end of test not met 169 7.19 Female 73 73 
47 non-reproducible 161 6.37 Female 74 74 
48 cough  159 9.62 Female 44 50 
49 Slow start 164 6.8 Female 74 75 
50 cough  174 6.72 Male   86 86 
51 non-reproducible 167 20.04 Male   47 60 
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52 end of test not met 169 9.33 Female 73 76 
53 Slow start 184 11.12 Male   62 68 
54 non-reproducible 159 6.83 Female 71 72 
55 non-reproducible 171 6.51 Male   75 75 
56 end of test not met 161 6.55 Female 76 77 
57 non-reproducible 174 9.74 Male   55 59 
58 non-reproducible 174 10.22 Male   65 69 
59 non-reproducible 178 6.27 Male   85 86 
60 non-reproducible 177 7.04 Male   85 85 
61 non-reproducible 179 6.89 Male   81 82 
62 Slow start 165 8.9 Female 73 75 
63 cough  155 6.69 Female 71 72 
64 non-reproducible 186 6.73 Male   75 75 
65 non-reproducible 178 12.18 Male   55 61 
66 cough  176 6.83 Male   65 66 
67 non-reproducible 159 8.14 Female 73 77 
68 end of test not met 172 7.87 Male   60 63 
69 end of test not met 155 6.02 Female 70 71 
70 end of test not met 174 13.06 Male   54 62 
71 end of test not met 159 8.08 Female 82 84 
72 non-reproducible 159 8.24 Female 53 55 
 
 Total (% of total) Male Female 
 72 39(54%) 33 (46%) 
Non-smokers:  35 18 17 
Ex-Smokers: 25 17 8 
Smokers:  12 4 8 
Age (Years) 60 58 62 
FET (Seconds) 8.71 9.29 8.02 
Height (Centimetres) 168  176 159 
FVC  2.98  3.64 2.21 
FEV6 2.86  3.45 2.15 
FEV1 2.14  2.58 1.62 
FEV1/FVC 70.3 69.1 71.8 
FEV1/FEV6 73.0  72.3 73.8 
Slow start 12 (16.6%) 6 (15.5%) 6 (18.2%) 
EOT not met 24 (33.4%) 14 (35.9%) 10 (30.3%) 
Not reproducible 22 (30.5%) 14 (35.9%) 8 (24.2%) 
Cough 10 (13.9%) 4 (10.2%) 6 (18.2%) 
Glottis closure 4 (5.6%) 1 (2.5%) 3 (9.1%) 
FVC: forced vital capacity; FEV1: forced expiratory volume in one second; FEVt: forced expiratory 
volume in t seconds; EOT: end of test;  
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APPENDIX F 
 
NHANES III PREDICTION AND LOWER LIMIT OF NORMAL 
 EQUATIONS FOR FEV1/FEV6% AND FEV1/FVC%  FOR CAUCAUSIAN 
 MALE AND FEMALE SUBJECTS AGED 8-80 YEARS  
 
 
  InterceptPRD Age InterceptLLN  R2 
Male subjects       
  Caucasian       
    FEV1/FEV6%  87.340  0.1382 78.372  0.2151 
    FEV1/FVC%  88.066  0.2066 78.388  0.3448 
Female subjects       
  Caucasian       
    FEV1/FEV6%  90.107  0.1563 81.307  0.3048 
    FEV1/FVC%  90.809  0.2125 81.015  0.3955 
* InterceptPRD is used for prediction equation and InterceptLLN is used (replaces 
InterceptPRD) for the lower limit of normal equation. Lung function parameter = b0 + b1 
* age.  
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APPENDIX G 
GARCIA-RIO PREDICTED EQUATIONS FOR HEALTHY CAUCASIAN 
EUROPEAN MALES AGED 65-85YRS 
 
 
 
Equation 
 
R2 
 
RSD 
 
FVC L 0.0001572H2–0.00000268A3+0.223 0.477 0.4458 
FEV1 L 0.0001107H2–0.0445A+2.886 0.464 0.3797 
FEV1/FVC % –0.00198A2+87.472 0.083 5.2655 
FEV0.5 L 0.02615H–0.0372A+0.538 0.411 0.3305 
FEV2 L 0.0001331H2–0.00000283A3+0.499 0.488 0.4066 
FEV3 L 0.0001414H2–0.0000028A3+0.420 0.488 0.4174 
FEV6 L 0.0001501H2–0.000298A2+0.869 0.483 0.4288 
FEV1/FEV6 % –0.0000172A3+85.536 0.086 5.0040 
FEF25% L·s–1 0.04185H–0.137A+8.947 0.226 1.5178 
FEF50% L·s–1 0.03174H–0.0754A+3.176 0.170 1.0573 
FEF75% L·s–1 0.009789H–0.0184A+0.355 0.163 0.2776 
PEF L·s–1 0.07092H–0.000939A2+0.347 0.221 1.7378 
FEF75–25% L·s–1 0.02635H–0.0604A+2.042 0.219 0.7241 
FEF75–85% L·s–1 0.007765H–0.00948A–0.229 0.149 0.1779 
TC25–50% s 0.00005571A2+0.153 0.045 0.2041 
MTT s 0.00002282A2+0.223 0.054 0.0760 
AEX L2·s–1 0.0007148H2–0.379A+18.788 0.397 3.3119 
PIF L 0.0002211H2–0.0909A+4.621 0.247 1.2465 
MIF50% L·s–1 0.0002133H2–0.0856A+4.128 0.221 1.2759 
FIV1 L 0.0001585H2–0.0526A+2.592 0.373 0.5967 
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The lower limit of the normal is computed as: predicted value–1.645xresidual standard 
deviation (RSD)  
R2: adjusted coefficient of determination 
 
GARCIA-RIO PREDICTED EQUATIONS FOR HEALTHY CAUCASIAN 
EUROPEAN FEMALES AGED 65-85YRS 
 
 
Equation 
 
R2 RSD 
 
FVC L 0.0003171H2–0.0351A–6.368BSA+0.05925W+3.960 0.589 0.3046 
FEV1 L 0.0001726H2–0.0326A–2.303BSA+0.000122W2+3.398 0.527 0.2741 
FEV1/FVC % –0.155H–0.184A+116.096 0.048 5.4974 
FEV0.5 L 0.00008072H2–0.0251A+1.436 0.432 0.2589 
FEV2 L 0.0001138H2–0.0334A+1.844 0.523 0.2963 
FEV3 L 0.0001218H2–0.0336A+1.774 0.529 0.3056 
FEV6 L 0.0003309H2–0.0346A–6.987BSA+0.06548W+4.152 0.566 0.3101 
FEV1/FEV6 % –0.181H–0.178A+120.544 0.058 5.3530 
FEF25% L·s–1 0.05351H–0.00000343A3–2.756 0.167 1.1193 
FEF50% L·s–1 0.03414H–0.0540A+0.890 0.188 0.8234 
FEF75% L·s–1 0.005960H–0.0150A+0.660 0.131 0.2467 
PEF L·s–1 0.0002283H2–0.0644A+4.001 0.209 1.1932 
FEF75–25% L·s–1 0.02030H–0.0440A+1.538 0.202 0.5828 
FEF75–85% L·s–1 –0.0644A+0.735 0.062 0.1345 
TC25–50% s 0.0000003057A3+0.288 0.025 0.1743 
AEX L2·s–1 0.0005499H2–0.158A+3.788 0.419 1.7560 
PIF L 0.03154H–0.0553A+2.139 0.153 0.9248 
MIF50% L·s–1 0.02934H–0.0566A+2.363 0.143 0.9552 
FIV1 L 0.03478H–0.143A+0.000006A3+4.701 0.411 0.3866 
The lower limit of the normal is computed as: predicted value–1.645xresidual standard 
deviation (RSD)  
R2: adjusted coefficient of determination  
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APPENDIX H 
1. Irish Thoracic Society (ITS), Galway 2005-Oral presentation 
(Irish Journal of Medical Science Supplement 3, Volume 174 Number 4) 
 
2. European Respiratory Society , Munich 2006-Thematic poster presentation 
Abstract Number: 253038 
 
 
 
Title: FEV1/FEV6 as an alternative to FEV1/FVC in diagnosing airway obstruction 
using USA and European reference values in an elderly Irish population. 
 
Janine M Kelly1, Patrick J Manning 1and Patrick G Goodman2. 1Respiratory,Bon 
Secours Hospital, Glasnevin, Dublin 9,Ireland and 2School of Physics, Dublin Institute 
of Technology, Kevin Street, Dublin 8,Ireland. 
 
Introduction: 
This study evaluates the use of FEV1/FEV6 as an alternative to FEV1/FVC in diagnosing 
airway obstruction, especially for patients who cannot provide a satisfactory FVC end 
of test criteria. This was done using US and European reference values with an elderly 
Irish patient group, age 65-85yrs, the only age group for which European reference 
values are available. 
 
Method: 
A retrospective analysis was conducted on spirometry data for 68 patients aged 65-
85yrs who exhaled for at least six seconds who met ATS criteria. Coefficient of 
variance for both reference sets and the sensitivity and specificity of FEV1/FEV6 for 
diagnosing airways obstruction as defined by FEV1/FVC was calculated. 
 
Results: 
 
 Using USA reference values Using European reference values 
Sensitivity % 100 100 
Specificity % 97.9 95.5 
Positive predictive value % 94.7 91.6 
Negative predictive value% 100 100 
Coefficient of variation % FEV1/FVC = 17.8% FEV1/FVC = 18.3% 
 FEV1/FEV6=13.7% FEV1/FEV6%=14.3% 
 
Conclusions: 
This study has shown reduced variability of FEV1/FEV6 compared to FEV1/FVC 
demonstrating that FEV6 has a role in spirometry testing, especially for patients unable 
to reach a satisfactory FVC endpoint. The agreement of FEV1/FVC and FEV1/FEV6 
using both reference sets and the sensitivity/specificity of FEV1/FEV6 in this cohort 
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support the validity of using FEV6 in the diagnosis of airway obstruction. This work 
highlights the need for updated European reference values for FEV6 for all age groups. 
 
 
 
 
